

Index

A

- Absorption of nutrients. *See* Bioavailability;
Intestinal absorption; *individual nutrients*
- Acceptable Macronutrient Distribution Ranges (AMDRs). *See also individual nutrients and life-stage groups*
defined, 14-15, 28, 39, 772, 941
evidence considered for, 15-16, 769
rationale for, 14, 28, 784
uses, 29, 941, 945, 946, 948-949
- Adaptation, nutritional
amino acid metabolism, 618, 619
basal metabolism, 201
to carbohydrate-free diet, 277-278, 293
defined, 149, 973
in energy balance, 149-151, 201, 220, 223-224, 452
glucose metabolism, 277-278
growth impairment as, 151, 220, 437
to high-fat diets, 452
pregnancy and lactation, 34, 47, 197, 290, 291, 650
to protein metabolism, 47, 276, 279, 605, 611, 650, 657, 694
to starvation, 277-279, 605
weight as, 150
- Adequate Intakes (AIs). *See also individual macronutrients and life-stage groups*
criteria used to derive, 7-8, 10-11, 44-46
defined, 3, 22, 26
derivation of, 28, 31, 32, 47
extrapolation between other age groups, 26-27, 31-32, 34, 46, 47, 283
indicators used to set, 28
methods used to set, 44-46, 47, 280-283, 385-390, 456-457, 460-461, 464, 465, 466-470, 471-472, 619-621, 662-665
prevalence of intakes above, 789
RDA compared, 6, 26-27
uncertainty in, 26, 44
uses, 26, 936, 939-940, 944-945, 946, 948
- Adiposity, 125, 130, 189, 200, 220, 379, 832.
See also Body fat content
- Adolescents, ages 9 through 18 years. *See also* Puberty/pubertal development
added sugars, 1206-1209, 1216-1219
ages 9 through 13 years, 35, 386, 463-464, 470, 624-627, 631, 665, 673-674, 769, 1126-1129, 1138-1143, 1172-1173, 1178-1181, 1206-1207, 1216-1217, 1232-1233, 1238-1239
ages 14 through 18 years, 35, 193, 201-202, 292, 293, 386, 389-390, 463-464, 465-466, 470, 471-472, 674-675, 729, 769, 1128-1129, 1143-1145, 1181-1183, 1208-1209, 1218-1219, 1232-1233, 1238-1239
AIs, 26-27, 33, 385-386, 388-389, 463-464, 470, 471-472, 632-633
AMDRs, 769, 816, 844, 945

- amino acids, 664-670, 673-675, 702-703
 aortic fatty streaks, 815
 aspartame, 702-703
 BMR, 178-179
 body composition and size, 142, 178,
 181, 626-629
 bone mineralization, density, and mass,
 66, 180
 brain development, 288-289
 carbohydrate, 284-285, 292, 1232-1233,
 1238-1239
 EARs, 33, 46-47, 284, 292, 293, 632, 664-
 669, 673-675
 EERs, 175, 176-182, 193, 201-202, 216-
 219
 energy intakes, 473, 474, 1206-1209,
 1216-1219, 1232-1233, 1238-1239
 extrapolation of data from adult values,
 26-27
 factorial methods, 628, 631
 fat (total dietary), 459, 945, 1232-1233,
 1238-1239
 fatty acids, 456, 1232-1233, 1238-1239
 fiber, 385-386, 388-389, 391, 394, 1232-
 1233, 1238-1239
 glucose metabolism, 288-289
 growth and development, 33, 142, 175,
 177, 181, 182, 459, 654
 lactation, 293, 389-390, 465-466, 471-472,
 659
 maintenance requirement, 667
 nitrogen balance studies, 624-627, 632,
 664-666
 nutrient intakes with added sugars,
 1206-1209, 1216-1219
 obese or overweight, 181, 216-219, 312,
 459, 1172-1173, 1178-1183, 1200,
 1202
 physical activity, 176-181, 182, 880, 883,
 902-907, 911-912, 924, 1126-1129,
 1138-1145, 1172-1173, 1178-1183
 polyunsaturated fatty acids, 463-464, 465-
 466, 469-470, 471-472
 pregnancy, 48, 193, 201-202, 292, 389,
 465, 471-472, 650-652, 654-655
 protein, 624-629, 631, 632-633, 665, 670,
 769
 RDAs, 285, 292, 293, 631-632, 655, 670,
 673-675
 reference weights and heights, 35, 136-
 137, 176, 178, 659, 670, 983
 saturated fatty acids, 474, 835, 1232-
 1233, 1238-1239
 special considerations, 216-219
 sugar intakes, 312, 323, 1206-1209, 1216-
 1219
 TEE, 176, 178, 181, 1126-1129, 1138-
 1145, 1172-1173, 1178-1183, 1200,
 1202
trans fatty acids, 456
 vitamin and mineral intakes, 1232-1233,
 1238-1239
 weight, 216-219, 650, 652, 653, 655
 Adults, ages 19 years and older. *See also*
 Age/aging; Lactation; Pregnancy
 added sugars, 295, 788-789, 1210-1215,
 1220-1225
 ages 19 through 50 years, 35, 46, 184,
 186-189, 205-213, 286, 288, 292, 293,
 296, 323, 371, 388, 389, 447, 450-452,
 464, 471-472, 548, 614, 633-645, 648,
 695, 887, 983-984, 701, 703, 720, 727,
 729, 730, 1146-1159, 1164-1167,
 1184-1187, 1190-1195, 1210-1211,
 1220-1223, 1234-1235, 1240-1241
 ages 51 years and older, 33-34, 66, 138,
 143-144, 289, 296, 303, 358, 371, 388,
 396, 398, 447, 450-452, 464, 548-549,
 602, 603, 608, 634, 660, 661, 697,
 704, 711, 723, 725, 734, 736-737, 841,
 887, 922, 1150-1153, 1158-1163,
 1186-1191, 1194-1199, 1214-1215,
 1224-1225, 1236-1237, 1242-1243
 AIs, 26, 33-34, 387-388, 464-466, 470-472
 allergies, 692
 AMDRs, 285, 769, 809, 826, 844, 941
 amino acids, 594, 599, 607, 613, 614,
 668, 669, 670-680, 686-688, 690-691,
 692, 703, 720, 726
 bioavailability of nutrients, 34
 BMI, 35, 36, 121, 124-130, 131, 310,
 1078-1087, 1098-1103
 body composition data, 1078-1103
 body fat content, 111, 124-125, 126, 128-
 130, 131, 1078-1101
 bone mineral density, 66
 brain utilization of glucose, 285-289
 carbohydrates, 265, 277, 285-289, 294-
 295, 769, 809, 1234-1237, 1240-1243
 catabolic stress, 594
 CHD risk, 303, 366, 387-388, 777-784,
 797-798

- cholesterol, 548-549
- dental caries, 296
- diabetes (type 2), 268, 388, 784-785
- dietary intakes, 294-295, 602, 695, 697, 1234-1237, 1240-1243
- EARs, 33, 34, 46-47, 285-289, 292, 293, 633, 643-644, 646-649, 668, 670-679
- EERs, 121, 124-130, 183-189
- energy expenditure, 108, 116, 122-123, 131, 138, 140-141, 143-144
- energy intakes, 474, 647, 1234-1237, 1240-1243
- energy metabolism, 33, 54, 108, 116, 289
- extrapolation of data to infants and children, 25, 26-27, 34, 46, 47, 284
- fat (dietary), 459-460, 769, 809, 1234-1237, 1240-1243
- fiber, 354, 358, 366, 387-389, 396, 398, 788, 809, 1234-1237, 1240-1243
- glucose metabolism, 285-289, 388, 784-785
- high fat, low carbohydrate diets, 792-810
- hyperinsulinemia, 784-785
- low fat, high carbohydrate diets, 772-792
- malnutrition, 608
- methodological considerations, 47-48
- monounsaturated fatty acids, 432
- nitrogen balance studies, 275, 287, 618, 633-643, 661
- nutrient intakes with sugars, 1210-1215, 1220-1225
- obese and overweight, 122-123, 792-797, 1184-1199, 1201
- peak bone mass, 33
- physical activity, 66, 138, 143-144, 183-184, 186-189, 883, 895-903, 911-912, 1184-1199
- polyunsaturated fatty acids, 433, 435, 464, 470-472, 478
- protein, 287-288, 595, 602, 605, 608, 611-612, 633-649, 660, 661, 668, 686-688, 690-691, 692, 695, 769, 841
- RDAs, 33, 47, 265, 289-290, 292, 293, 603, 644-645, 649, 667-669, 679-680
- reference heights and weights, 35, 124, 125, 126, 128-130, 983-984
- renal function, 34
- reserve capacity and functioning, 33-34
- saturated fatty acids, 474, 835, 1234-1237, 1240-1243
- special considerations, 202-213, 220
- sugar intakes, 323, 789, 792, 1210-1213, 1220-1225
- TEE, 161-164, 183, 203, 1146-1165, 1184-1199, 1200-1201
- vitamin and mineral intakes, 1234-1237, 1240-1243
- weight and height, 143, 183, 184, 220, 1078-1081, 1088-1091
- weight maintenance, 773-777
- Adverse effects. *See also individual nutrients*
defined, 84, 973
insufficient evidence of, 102-103, 970-971
nutrient–nutrient interactions, 85, 95
- Aerobics Center Longitudinal Study, 912
- African Americans
breast cancer, 379
energy expenditure, 145-146, 179
fiber, 379
pubertal development, 33
- Age/aging. *See also Adolescents; Adults; Children; Infants; Life-stage groups*
BMR, 131, 143
carbohydrate–lipid oxidation balance, 922
energy expenditure, 117, 143-144, 157, 158, 159-161, 181, 183
and energy requirements, 183, 647
fat absorption, 447, 450-452
glucose metabolism, 289
insulin resistance, 62
physical activity, 143-144, 922, 924
and protein reserve, 595, 602, 640-641, 642
reporting of dietary intakes, 117
RMR, 143
sensitivity to nutrient toxicity, 92
and sugar intakes, 323
TEF, 134, 143, 165, 171, 179
weight gain, 143, 167
- Alanine (dispensable), 276, 591, 593, 594, 596, 597, 604, 605, 606, 696-697, 736, 992-993
- Alaska Natives, 275, 284, 693
- Albumin, 304-305, 430, 602, 609, 610
- Alcohol
dietary intakes, 49, 110, 1064-1065
energy contribution, 109, 771, 1064-1065
and fatty acid oxidation, 109, 453

- by life stage and gender group, 1064-1065
 - oxidation rate, 108-109
 - TEF, 109-110
- Alcoholics and alcoholism, 110, 704
- Aldosterone, 543
- Allergic reactions, 295, 396, 397, 399
- α -Ketoglutarate, 604, 605
- α -Linoleic acid. *See also* Polyunsaturated fatty acids, *n*-3
 - AIs, 8-9, 11, 423, 466-472, 834, 944-945
 - AMDRs, 15-16, 770, 834-835
 - and CHD, 427, 770, 827, 828, 829
 - deficiency, 9, 423, 427, 439-440, 443-445, 470, 472
 - dietary intakes, 478, 834
 - food sources, 478, 771, 834
 - function, 423, 427, 435, 445, 466
 - interaction with linoleic acid, 447, 453-455, 472, 825
 - and learning behavior, 439, 445
 - metabolism, 434-435, 445-446, 468, 472
 - parenteral nutrition and, 444
 - protective effects, 427, 770
 - sources, 427, 447
 - supplementation, 444
 - and vision, 439, 440, 468
- Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, 483
- Altitude, and energy expenditure, 149
- Amino acids. *See also* Protein; *individual amino acids*
 - absorption, 621
 - adaptations in metabolism, 618, 619
 - adverse effects of, 696, 697-698, 701-703, 705-708, 711-712, 713-717, 720, 721-723, 724-726, 727, 729, 730-733, 734-735
 - AIs, 662-663
 - alcoholism and, 704
 - animal studies, 671, 696, 697-698, 701-702, 703, 705, 707-708, 711-712, 713-714, 720, 721-722, 724, 725-726, 727, 729, 730-732, 734-735
 - and appetite or eating behavior, 707, 709, 710, 713, 730, 731-732
 - and asthma, 716-717
 - and behavior, 697, 701, 713, 714, 721, 727, 729
 - bioavailability, 685
 - and body fat, 713
 - and brain chemistry, 704-705, 707, 709, 710, 711, 714, 721, 731, 732, 734, 735
 - branched-chain, 604, 616, 660, 704-711; *See also* Isoleucine, Leucine, Valine
 - and cancer, 54, 698-699, 700, 708, 710, 711, 713, 719, 722, 732, 843
 - and carbohydrates, 275, 276, 701, 731, 732-733
 - carbon metabolism, 605-607
 - catabolism, 278, 594, 603-608, 616, 617, 704, 712
 - and CHD risk, 726
 - chemistry, 590, 592-593
 - Chinese restaurant syndrome, 714, 715-716
 - composition of proteins, 279, 621, 666, 682, 685-686
 - deficiency, 662
 - deposition rate, 672-675
 - dermal effects, 733-734, 735
 - developmental studies, 708-710, 724, 732
 - diabetes and, 704
 - dietary intakes, 692, 696, 697, 700, 701, 704, 711, 712, 720, 721, 723, 725, 727, 729, 730, 731, 734, 736, 992-1027
 - digestibility, 621
 - direct amino acid oxidation method, 615-617, 618, 619, 670-671, 676-678
 - dose-response assessment, 697, 699-700, 703, 711, 712, 717, 719, 720, 723, 725, 726, 728, 729, 730, 731, 733-734, 736
 - EARs, 589, 619, 664-679, 680-681, 688
 - excretion, 604
 - factorial estimate, 614, 666-669
 - food sources, 48, 712-713, 714
 - free, 596-597, 599, 602, 603, 620, 692, 721
 - function, 9, 38, 589, 590, 696, 697, 701, 704-705, 712, 720-721, 725, 729, 731, 734, 736
 - and gastrointestinal disturbances, 698, 700, 714, 720, 722, 724, 726, 733
 - genotoxicity, 720
 - gluconeogenesis from, 276, 278, 288-289, 604, 606
 - and growth, 598, 607, 665, 666, 669, 697, 701, 707, 710, 713, 719, 720, 721, 724, 725, 728

- hazard identification, 696-699, 700, 701-703, 704-710, 711-717, 718-719, 720, 721-723, 724-726, 727, 729, 730-733, 734-735
- and herpes infections, 724
- high-protein diets and, 712
- homeostasis, 595-598
- hormonal effects, 715
- human studies, 608-699, 702-703, 705-706, 712, 714-715, 720, 722-723, 724-725, 726, 727, 729, 730, 731-733, 735
- imbalances in, 707, 708-709, 710, 726
- and immune function, 697-698, 699
- indicator amino acid oxidation method, 617-619, 670-671, 676, 677, 678
- indicators for estimating requirements, 613-619
- individual variability in requirements, 614, 665-666, 679
- insulin sensitivity, 696, 701, 705, 710
- intake assessment, 736-737
- interactions with other nutrients, 721-723, 725, 726, 731
- by life stage and gender group, 662-682, 992-1027
- limiting, 602, 611, 614, 669, 685, 689, 690, 691
- and lipid profiles, 721, 724
- liver function and, 704, 705, 721
- losses, 601, 614
- low-protein diets, 697, 707, 709, 721, 731-732
- maintenance, 666, 667-669, 672-675
- and malnutrition, 704
- maple syrup urine disease, 704, 706
- metabolic disorders, 697, 700, 704, 705, 706, 710, 714, 727, 728, 735
- metabolic pathways, 597-598, 600, 617, 660, 697, 701, 704, 705, 717, 719, 724, 726, 728-729, 731
- neurological effects, 696, 699, 701-702, 703, 704-705, 706, 711, 714, 715, 717, 718, 719, 727, 728, 733
- nitrogen balance studies, 612, 613-614, 618, 662, 664-666, 670-671, 676, 677, 678, 688
- nitrogen metabolism, 278, 603-605, 718, 720
- nitrogen utilization through nonprotein pathways, 607-608
- nutritional and metabolic classification, 593-594
- and obesity, 701, 704, 732
- ophthalmologic effects, 711, 714, 720, 722, 729, 734, 735, 736
- parenteral nutrition and, 699, 705, 714, 718, 719, 722-723
- and physical exercise, 702, 705-706
- planning and assessing intakes, 961-963
- plasma amino acid response method, 614-615, 670-671
- precursors of nonprotein products, 608
- protective effects, 726
- quality of protein source, 661, 662, 684-690, 721
- RDAs, 47, 672-675, 679-680, 681, 682
- reproductive effects, 701, 712, 713, 715
- research recommendations, 737-738
- risk characterization, 737
- scoring, 14, 589, 662, 685, 686-691
- selection of indicators for estimating requirements, 613-619
- and somnolence, 698, 700, 722, 733
- special considerations, 728
- and starvation, 693, 704
- supplementation, 695-735
- synthesis, 275, 701, 712, 717, 723, 729, 734
- and taste and smell acuity, 722
- teratogenic effects, 708, 728
- trauma and, 596, 605
- 24-hour amino acid balance method, 616-617, 670-671, 676, 677
- ULs, 695-737
- variance in requirements, 688
- and weight, 697, 698, 700, 707, 709, 713, 721, 724, 730, 731-732, 734
- Amino sugars, 684
- Ammonia, 56, 375, 377, 603, 604, 605, 684, 697, 714, 717-718, 719
- Amylopectin, 267-268, 269, 272
- Amylose, 267, 272
- Animal studies
- advantages, 94-95, 97
- amino acids, 671, 696, 697-698, 701-702, 707-708, 711-712, 713-714, 720, 721-722, 724, 725-726, 727, 729, 730-732, 734-735
- carbohydrate, 40, 275
- cholesterol, 548, 562
- colon cancer, 377

- dose-response assessment, 96, 98, 100
 - extrapolation of data from, 40, 87, 95, 97, 98, 100, 101, 492, 562, 1245-1246
 - fat, 40
 - fiber, 351, 361, 377
 - hazard identification, 94-95, 96, 696, 697-698, 701-702, 707-708, 711-712, 713-714, 721-722, 724, 725-726, 727, 729, 730-732, 734-735
 - nitrogen balance studies, 671
 - polyunsaturated fatty acids, 444-445, 492
 - pregnant animals, 709, 726
 - protein, 40
 - relevance of, 39, 40, 94, 96, 703, 705, 711, 727
 - uncertainties in, 100, 1245-1246
 - Apolipoprotein A-I, 61
 - Apolipoprotein B100, 503
 - Apolipoprotein CH, 429
 - Apolipoprotein E, 544
 - Apoptosis, 429
 - Apoptosis, 55, 833, 837-838
 - Appetite, 383, 707, 709, 710, 713, 730, 731-732, 795
 - Arabinose, 345
 - Arachidonic acid, 425, 426, 433-434, 435, 438, 439, 440, 442, 443, 444, 446-447, 453-454, 455-456, 465, 469, 472, 476, 478, 824, 838
 - Arginase, 605
 - Arginine (dispensable), 591, 593, 594, 597, 605, 608, 697-700, 709, 712, 717, 724, 736, 994-995
 - Arginine glutamate, 714
 - Argininosuccinic acid synthetase, 697, 700
 - Arizona Wheat-bran Fiber Trial, 374
 - Arteriosclerosis, 130, 842
 - Asians, obese, 352
 - Asparagine (dispensable), 591, 593, 594, 700
 - Aspartame, 695, 702-703, 727
 - Aspartic acid/aspartate (dispensable), 591, 592, 593, 594, 597, 604, 605, 608, 695, 709, 736, 996-997
 - Association of Official Analytical Chemists International, 340, 344
 - Assessment of nutrient intakes
 - added sugars, 957
 - AI and, 939-940, 944-945
 - AMDR and, 941, 945
 - amino acids, 960-963
 - biochemical approach, 944
 - carbohydrate, 956-957
 - cut-point method, 943
 - EAR and, 938-939, 943-944
 - energy, 48, 225, 954-956
 - fat, 959
 - fiber, 957-958
 - of groups, 16-18, 941-945
 - of individuals, 937-941
 - polyunsaturated fatty acids, 959-960
 - probability approach, 942-943, 944
 - protein, 960-961
 - RDA and, 938-939, 944
 - UL and, 940, 945
 - Asthma, 396, 399, 716-717
 - Atherogenic dyslipidemia, 777
 - Atherogenic lipid profile, 802
 - Atherogenic lipoprotein phenotype, 777, 782
 - Atherosclerosis, 59, 485-486, 546, 548, 549, 560, 562, 563, 823-824, 826, 836-837, 840
 - Atherosclerosis Risk in Communities Study, 563
 - Athletes, 115. *See also* Physical activity
 - amino acid supplements, 702, 706
 - endurance training, 660
 - energy balance, 221-223, 452
 - high-carbohydrate diet, 452
 - high-fat diet, 452
 - lipoprotein profile, 61
 - low fat, high carbohydrate diet, 773
 - protein, 660-661
 - resistance training, 660
 - runners, 61, 773
 - skeletal health, 66
 - Autoimmune diseases, 487
- ## B
- Balance studies. *See also* Nitrogen balance studies
 - cholesterol, 543-544
 - defined, 40
 - limitations of, 40-41, 617, 676
 - methionine, 677
 - 24-hour amino acid method, 616-617
 - zinc bioavailability, 394
 - Basal energy expenditure (BEE)
 - defined, 112
 - DLW data, 1104-1202
 - fat-free mass and, 128, 186
 - gender differences, 141, 217

- and MET rate, 888
- obese and overweight individuals, 217
- prediction, 114, 171, 178-179, 186, 205, 217
- Schofield equations, 171, 178-179, 186
- and weight, 116, 141, 150, 183, 184, 186, 206-213, 888
- Basal metabolic rate (BMR), 25
 - adaptations, 201
 - adolescents, 178-179
 - aging and, 131, 143
 - altitude and, 149
 - body composition and size and, 131, 141
 - and carbohydrates, 196
 - children, 141, 171, 1114-1121
 - climate and, 148
 - defined, 112
 - and energy expenditure, 112-114, 115, 131, 141, 164-165, 171, 178-179, 185, 188-190, 195
 - and energy requirement, 164-165, 171, 178-179, 185, 188-190, 195-196
 - ethnic differences, 146
 - FFM and, 139
 - gender differences, 141
 - infants, 164-165, 1106-1114
 - lactation, 195-196
 - measurement, 165, 171, 185, 188
 - menstrual cycle and, 140, 141
 - pregnancy, 185, 188-191, 291
 - protein balance and, 598
 - sedentary individuals, 115
- Basal requirement, 24
- Beans. *See* Legumes
- Behavior. *See also* Eating behavior
 - amino acid intake and, 697, 701, 713, 714, 721, 727, 729
 - breastfed infants, 621
 - learning, 439, 445, 446, 447, 697, 713, 729
 - polyunsaturated fatty acids and, 439, 445, 446, 447
 - sugar intake and, 295-296, 323
- Bengal gram, 366-367
- β_3 -Adrenergic receptor gene, 145
- β -Glucans (dietary or functional fiber), 345, 355-356
- β -Hydroxybutyrate, 285, 430
- Bioavailability of nutrients
 - age/aging and, 447, 450-452
 - amino acids, 685
 - balance studies and, 394
 - defined, 93, 973
 - factors affecting, 29-30, 93-94, 271, 281
 - fat intake and, 424, 785, 788-792
 - fiber consumption and, 29, 94, 348, 351-352, 369, 382, 391, 394-395, 397-398, 838
 - in human milk, 431, 447, 621, 944
 - in infant formula, 26, 31, 45, 431, 940, 944, 946
 - nutrient-nutrient interactions and, 93, 271, 281, 424
 - and risk assessment, 93-94, 98
 - from supplements, 29, 93, 94
- Biomarkers of disease, 41
- Bladder cancer, 708, 710
- Bleeding time, 492-493
- Blood pressure. *See also* Hypertension
 - amino acids and, 735
 - fiber and, 60
 - physical activity and, 60
 - polyunsaturated fatty acids and, 59, 829
 - trans* fatty acids and, 504
 - weight and, 204
- Body composition and size. *See also* Body fat content; Fat-free mass; Fat mass; Obesity and overweight
 - adolescents, 142, 178, 181
 - adults, 1078-1103
 - and BMR, 131, 141
 - CLA and, 836-837
 - and energy expenditure, 65, 112, 117, 131-135, 138, 139, 141
 - gender differences, 128, 142, 1078-1103
 - genetic factors, 144, 146
 - NHANES III data, 124, 125, 130, 982, 1078-1103
 - pregnancy and, 188, 191-192
 - protein deposition, 626-629, 644
 - and reporting of dietary intakes, 117
 - research recommendations, 225, 240
 - and sensitivity to nutrients, 92
 - and TEE, 132
 - undernutrition and, 220
- Body fat content. *See also* Body Mass Index; Fat mass
 - adults, 111, 124-125, 126, 128-130, 131, 1078-1101
 - amino acid intake and, 713
 - bioimpedance data, 124
 - BMI and, 121, 124-125, 126, 128-130, 1080-1087, 1098-1101

- and cancer, 379
- gender differences, 1078-1101
- height and, 125, 128-130, 1078-1081, 1088-1089
- infants, 142, 621
- obesity, 126
- physical activity and, 57, 61, 139, 180, 181
- protein intake and, 843
- reserves, 111, 220
- and triceps skinfold, 125, 128, 1080-1081, 1086-1087, 1092-1093, 1100-1101
- and waist circumference, 1084-1085, 1094-1099
- and weight, 1090-1091
- Body Mass Index (BMI)**
 - adults, 35, 36, 121, 124-130, 131, 310, 1078-1087, 1098-1103
 - and body fat content, 121, 124-125, 126, 128-130, 1080-1087, 1098-1101
 - and cancer, 238-239
 - and CHD, 124, 232-233
 - children, 35, 36, 65, 130-131, 216, 814, 1114-1121
 - and chronic disease, 224, 226-239, 303
 - cutoffs, 121, 126
 - defined, 121
 - and diabetes type 2, 124, 226-229
 - fat intake and, 814
 - fiber consumption and, 352, 379, 383, 384
 - gender differences, 125-129, 1078-1087, 1098-1103
 - glycemic index and, 313
 - healthy, 121, 124, 126
 - and height, 1080-1081
 - as indicator of energy requirement, 121, 124-131
 - infants, 1106-1114
 - methodological issues, 121, 124-125
 - and mortality, 484
 - obesity, 126, 204, 216, 310, 313
 - PAL and, 220, 223, 814, 911
 - previous median vs. new median, 35
 - protein intake and, 843
 - reference heights and weights and, 35, 36, 124, 125, 126, 127-130
 - saturated fatty acid intake and, 484
 - sugar intake and, 65, 310, 313, 316-319
 - and triceps skinfold, 1080-1081, 1086-1087, 1100-1101
 - waist circumference used with, 124-125, 127, 1080-1081, 1084-1085, 1098-1099, 1102-1103
 - and weight, 1080-1081
- Body weight.** *See* Weight
- Bogalusa Heart Study,** 307, 310, 314-315, 792-793, 815
- Bone mineral density,** 66, 180, 276, 928
- Brain**
 - amino acids, 704-705, 707, 709, 710, 711, 714, 721, 724, 731, 732, 734, 735
 - carbohydrate utilization, 38, 265, 273, 276, 277, 278, 279, 280, 284, 285-289, 430
 - chemistry, 704-705, 707, 709, 710, 711, 714, 721, 731, 732, 734, 735
 - cholesterol synthesis by infants, 545, 548
 - glucose metabolism, 38, 265, 273, 276, 277, 279-280, 285-289
 - macronutrients needed by, 771
 - pituitary adenomas, 396
 - polyunsaturated fatty acid deficiency and, 444-445, 466, 468
- Bran,** 350, 353, 355, 356, 359, 367, 368, 371, 372, 378, 394, 395, 838
- Breast cancer**
 - arginine and, 698-699, 700
 - BMI and, 238-239
 - case-control studies, 54, 378
 - cholesterol intake and, 568, 574-575
 - conjugated linoleic acid and, 837, 838
 - cross-cultural studies, 54, 377-378
 - epidemiological studies, 54
 - fat intake and, 54, 55, 486, 512-513, 808, 843
 - fiber intake and, 56, 377-380
 - intervention studies, 378-379
 - monounsaturated fatty acid intake and, 819
 - physical activity and, 57
 - polyunsaturated fatty acids and, 825, 833
 - prospective studies, 378
 - protein intake and, 843-844
 - sugar intake and, 319-320
- Breastfeeding.** *See also* Human milk; Infants; Lactation
 - and energy expenditure, 165
 - recommendations, 31, 45, 171, 281, 662
- Butyrate,** 56, 348, 349, 361, 371, 375

C

- Calcium, 281, 391, 394, 431, 592, 789, 790-793, 811, 812, 813, 835, 838, 840, 841, 1204-1211, 1214-1221, 1224-1225, 1228-1243
- Canada
 dietary intake data, 295, 473, 479, 481, 692, 1066-1075
 fiber definitions and guidelines, 340, 349
 Food Guide to Healthy Eating, 771
 human milk intake and composition, 172-173
 physical activity recommendations, 883
 Canadian National Institute of Nutrition, 979
 Canadian Paediatric Society, 31, 32, 45, 46
 Canadian Society of Exercise Physiology, 883
- Cancer. *See also individual histological sites*
 amino acids and, 54, 698-699, 700, 708, 710, 711, 713, 719, 722, 732, 843
 BMI and, 238-239
 body fat and, 379
 carbohydrate intake and, 55, 319-321
 cholesterol and, 54, 568, 570-579
 CLA and, 427
 energy intake and, 54
 evidence about dietary factors, 53
 fat intake and, 54-55, 375, 376, 484, 486, 512-513, 808
 fiber intake and, 54, 55-56, 319, 321, 339, 373-380, 396, 398
 glycemic index of foods and, 310-311, 319, 321
 high fat, low carbohydrate diets and, 808
 hormone-related, 56
 monounsaturated fatty acids and, 55, 486, 819
 physical activity and, 56-57
 polyunsaturated fatty acids and, 54, 824-825, 833-834
 protective effect of nutrients, 54, 55, 819, 833-834
 protein intake and, 54, 843-844
 sugars and, 54, 55, 319-320, 321, 323
- Caproic acid, 425
- Caprylic acid, 425
- Carbohydrate, dietary. *See also* Glucose; Glycemic index; High fat, low carbohydrate diets; Low fat, high carbohydrate diets; Starch; Sugar; *individual life-stage groups*
 adaptation to starvation, 277-278, 293
 adverse effects of overconsumption, 295-323
 aging and, 289
 AIs, 32, 280-283, 944
 AMDRs, 15, 285, 769, 785, 809, 816
 amino acids and, 275, 276, 701, 731, 732-733
 animal derived, 342; *See also* Fiber and BMR, 196
 brain utilization, 38, 265, 273, 276, 277, 278, 279, 280, 284, 285-289, 430
 Canada, 295, 1068-1069
 and cancer, 55, 319-321
 and CHD, 59, 303, 797, 798-799, 800-801
 classification, 265-266
 clinical effects of inadequate intakes, 275-276
 compared to other nutrient intakes, 1226-1243
 and dental caries, 296-297
 and diabetes type 2, 63, 302, 303, 306-307, 785
 dietary intakes, 46, 65, 265, 294-295, 770-771, 943, 944, 1032-1035, 1068-1069, 1226-1243
 digestion, 272
 EARs, 4, 6, 277-280, 284, 285-289, 290-293
 energy contribution, 280, 281, 294-295, 770-771, 813, 1034-1035, 1226-1243
 epidemiological studies, 783, 785, 800-801
 fatty acid synthesis, 275, 277, 433
 food sources, 265, 280-281, 294, 771
 function, 4, 38, 265
 and growth, 280-281, 922-923
 hazard identification, 295-321
 high-carbohydrate diets, 295, 297, 438, 769, 772-792, 795
 in human milk, 281-283, 292
 intake assessment, 323
 intervention studies, 785, 786-787
 intestinal absorption, 60, 272-273, 281, 323, 369
 by life stage and gender group, 6, 280-293, 988-991, 1032-1033, 1068-1069
 and lipid oxidation, 917-923
 and lipid profile, 275, 277, 278-279, 297-303, 781, 782-784
 low carbohydrate diets, 293, 430, 784, 792-810

- malabsorption, 397
- and mental health, 276
- metabolism, 38, 64, 190, 196, 273-275, 424
- and micronutrient inadequacies or excesses, 812, 816, 1226-1243
- and obesity, 65, 275, 307, 310-319, 769
- and physical activity, 64, 318-319, 452, 917-923
- planning intakes, 956-957, 964
- RDAs, 4, 6, 47, 265, 285, 289-290, 292, 293
- research recommendations, 323-324
- special considerations, 283, 293
- TEF, 110, 114
- total, 63, 956-957
- Carbohydrate-free diet, 277-278, 281, 287-288, 289, 293, 701
- Carbon metabolism, 605-607
- Carboxymethylcellulose gum, 367, 382
- Carboxypeptidases, 599
- Cardiac arrhythmias, 59, 60, 427, 829, 927
- Cardiovascular disease. *See also*
 - Atherosclerosis; Coronary artery disease; Coronary heart disease
 - cholesterol intake, 546, 548, 549, 560, 562
 - lipid profile and, 302, 562-569
 - monounsaturated fatty acids and, 485-486
 - physical exercise and, 60-61, 927
- Carnitine, 430, 607, 608, 723, 724
- Carnosine, 721
- Carotenoids, 424, 785, 792-793
- Catecholamines, 608, 735
- Caucasians
 - carbohydrate-free diet, 275
 - energy expenditure, 145-146
 - pubertal development, 33
- Cell growth and proliferation, 55
- Cell surface adhesion proteins, 490
- Cellulose (dietary or functional fiber), 344-345, 348, 350, 351, 356, 358, 359, 367, 371, 372, 382, 390, 394
- Centers for Disease Control and Prevention, 130, 216
- Cereals and cereal fiber, 55-56, 359, 363, 364, 369, 370, 373, 377, 378, 380-381, 387, 388, 394, 399, 788
- Chicago Western Electric Study, 562, 826-827, 828
- Children, ages 1 through 8 years. *See also*
 - Life-stage groups; Toddlers
 - added sugars, 294, 812-813, 816, 1204-1205
 - AIs, 26-27, 32, 34, 385-386, 463, 469-470
 - allergies, 692
 - AMDRs, 769, 816, 826, 844, 941, 945
 - amino acids, 25, 589, 614, 619, 664-670, 672-673, 686, 687, 689, 702-703, 720
 - aortic fatty streaks, 815
 - aspartame, 702-703
 - BMI, 35, 36, 65, 130-131, 216, 310, 814, 1114-1127, 1128-1139
 - BMR, 141, 171, 1114-1121
 - bone mass, 66
 - brain development, 284, 286-287, 288-289, 608-609
 - carbohydrates, 65, 265, 284-285, 294, 295, 769, 813, 1226-1231
 - chronic disease risk in adulthood, 130, 814-815
 - congenital defects of amino acids, 619, 697
 - constipation, 370-371, 385-386
 - dental caries, 296
 - derivation of DRIs, 32
 - diarrhea, 438
 - EARs, 25, 32, 34, 46-47, 284, 631, 664-669, 672-673
 - EERs, 107, 130-131, 168-170, 171, 174-177, 216-219
 - energy expenditure, 116, 134-135, 138, 141, 146, 148, 161-164, 174, 1114-1127
 - energy intakes, 54, 65, 170, 386, 473, 474, 814, 1226-1231
 - epilepsy, 284
 - extrapolation of data from adults to, 25, 26-27, 34, 47, 284
 - factorial method, 628, 631, 666-669
 - fat (dietary), 437, 438, 441, 459, 769, 810, 814-816, 945, 1226-1227, 1230-1231
 - fatty acids, 456, 1228-1231
 - fiber, 370-371, 385-386, 1226-1227, 1230-1231
 - glucose metabolism, 286-287, 288-289
 - growth, 32, 47, 134, 142, 151, 167-168, 174, 175, 221, 222, 437, 441, 456, 459, 609, 611, 810-811, 839-840, 922-923
 - high fat, low carbohydrate diets, 814-816

- hyperactivity, 295
hypercholesterolemia, 811
lipid profiles, 811, 814-815
low fat, high carbohydrate diets, 438, 810-814
malnutrition, 167, 608-609, 839
methodological considerations, 25, 47-48
micronutrient intakes with
 macronutrients, 220, 811-814, 816, 1204-1205, 1228-1231
nitrogen balance studies, 624-627, 664-666
of obese parents, 133
obesity or overweight, 65, 130, 134, 140, 153, 216-219, 307, 310, 312-313, 459, 811, 814, 923, 1168-1179, 1200, 1202
PAL, 166, 1122-1127, 1128-1139, 1168-1179
phenylketonuria, 619
physical activity, 66, 138, 140, 146, 171, 174, 880, 883, 902-907, 911-912, 924
polyunsaturated fatty acids, 438, 444, 463, 469-470
protein, 25, 284, 608-609, 611, 624-629, 631, 667-669, 686, 687, 689, 692, 769, 811, 839-840
RDAs, 25, 34, 47, 265, 285, 631-632, 670, 672-673
saturated fatty acids, 474, 816, 835, 1226-1227, 1230-1231
special considerations, 216-219
stunting, 151, 217, 220, 221, 222, 811, 840
sugar intakes, 307-310, 813-814, 1204-1205
TEE, 134-135, 148, 161-164, 166, 174, 217, 1114-1127, 1128-1139, 1168-1179, 1200, 1202
TEF, 134, 171
toddlers (1 to 3 years), 32, 35, 130, 132-135, 166, 167-170, 284, 285, 386, 463, 470, 626-628, 631, 632, 664, 672, 686, 687, 689, 769, 816, 1106-1123, 1128-1129, 1226-1231
trans fatty acids, 456
UL derivation for, 34
underweight, 130, 811
urea synthesis defects, 699
wasting, 840
weight control, 216-219
weights and heights, reference, 34, 35, 130, 132-137, 176, 178, 983
Chinese restaurant syndrome, 715-716
Chitin and chitosan (functional fiber), 345, 351-352, 384, 395-396
Chloride, 725
Cholesterol (dietary)
 absorption, 4, 60, 359, 369, 543-544, 561
 animal studies, 548, 562
 adverse effects of, 549, 558-573
 balance studies, 543-544
 and cancer, 54, 568, 570-579
 and cardiovascular disease, 546, 548, 549, 560, 562
 and CHD, 58, 542, 548, 562-569, 572, 573, 836
 and diabetes type 2, 563
 dietary intake, 549, 550-559, 563, 960, 1058-1059
 dose-response assessment, 568-573
 epidemiological studies, 562-569
 food sources, 48, 544, 545, 546-549, 836
 function, 4, 542, 543
 hazard identification, 549-568
 high cholesterol diets, 545, 836
 by life stage and gender group, 546-549, 1058-1059
 and lipid profile, 544-545, 548-562, 563, 568-569, 573
 and lipoprotein metabolism, 544-545, 548-562, 563, 568-569, 573
 low cholesterol diets, 546, 561, 835
 metabolism, 4, 429, 544-546, 562
 oxidation products, 545-546
 reducing intakes, 836
 research recommendations, 574-575, 578
 risk characterization, 573-574
Cholesterol (plasma/serum total), 572. *See also* HDL cholesterol; LDL cholesterol
 amino acids and, 721, 724
 and cardiovascular disease, 546, 548, 549, 560, 562
 and CHD, 58, 542, 548, 562-569, 572, 573, 836
 cholesterol intakes and, 550-561
 fat intake and, 58, 544, 550-559, 560, 809
 fiber intake and, 4, 59-60, 339, 351, 352, 354, 355, 356, 357, 358-359, 360, 361, 365-368
 genetic factors, 58, 544, 545, 546, 561-562
 glycemic index and, 302

- interindividual variation, 560-561, 562
monounsaturated fatty acids and, 58, 486, 817-818
polyunsaturated fatty acids and, 58, 59, 560
protein intake and, 60, 840
saturated fatty acid intake and, 481, 482, 560, 561, 809
trans fatty acids and, 58, 494-495
- Chronic diseases. *See also individual diseases*
BMI and, 224, 226-239, 303
body weight gain and, 224, 226-239
fat-related risks, 437-438, 460
knowledge gaps on intake relationships to, 771-772, 970
physical activity and, 912-917
preventive effects of macronutrients, *See* Protective effects of macronutrients
protein intakes and, 694
- Chylomicrons, 429, 430, 432, 543, 544
- Citric acid cycle, 430, 606
- Citrulline, 604, 607, 717
- Climate, and energy expenditure and requirements, 146-149
- Collagen, 593, 595, 729
- Colon cancer
ammonia and, 375, 377
animal studies, 377
BMI and, 238-239
cholesterol intake and, 568, 576-577
colonic adenomas, 56, 238-239, 321, 371, 374, 375-376, 398
epidemiological studies, 373-374
fat intake and, 54, 55, 371, 486, 514-515, 808
fiber intake and, 55-56, 321, 348, 373-377
glycemic index of diet and, 310-311, 321
intervention studies, 374-375, 376-377
markers for, 374
monounsaturated fatty acids and, 819
physical activity and, 56-57
polyunsaturated fatty acids and, 833
protein intake and, 843
risk factors, 373
- Colon health, fiber and, 55-56, 339, 348, 358, 370-377, 385-386, 388
- Colonic adenomas, 56, 238-239, 321, 371, 374, 375-376, 398
- Colorectal cancer, 54, 55, 321, 486, 514-515, 808, 833, 837
- Conjugated linoleic acid (CLA)
and body composition, 836-837
and cancer, 427, 836-838
dietary intakes, 481
evidence considered for estimating requirements, 447
food sources, 480-481
function, 428-429
metabolism, 428
protective effects, 428, 836-838
supplements, 837
- Constipation, 353, 355, 358, 370-371, 372, 379, 385-386, 388
- Continuing Survey of Food Intakes by Individuals
adjustments to data, 49-50
dietary intake data, 294-295, 314-315, 391, 457, 461, 473, 474, 477, 478, 480, 549, 695, 788, 790-791, 799, 943, 1028-1065, 1226-1243
survey design, 49
- Copper, 721, 723, 790-791
- Cori cycle, 287, 607
- Corn syrups, 266, 294
- Coronary artery disease, 60-61, 434, 563, 815, 842-843. *See also* Coronary heart disease
- Coronary heart disease
amino acids and, 726
aortic fatty streaks during childhood and, 815
BMI and, 124, 232-233
carbohydrate intake and, 59, 303, 797, 798-799, 800-801
cholesterol intake and, 58, 542, 548, 562-569, 572, 573, 836
epidemiological studies, 362-365, 562-569, 797-798, 800-801, 817, 820-821, 826-828
fat intake and, 58-59, 437-438, 460, 769, 797-799, 802
fiber intake and, 59-60, 322, 339, 356, 362-368, 369, 387-388, 389, 563
gender and, 363, 364
genetic factors, 57
glycemic index and, 303, 308-311
high fat, low carbohydrate diets, 797-802, 814-815
homocysteine and, 726
intervention studies, 365-368, 798-799, 817-818, 821, 828-831

- lipid profile and, 57, 60, 356, 481-484, 542, 548-549, 562-569, 573, 798-799, 815
 - low fat, high carbohydrate diets and, 437-438, 772, 777-784
 - monounsaturated fatty acids and, 58-59, 817-818
 - obesity and overweight and, 130, 815
 - physical activity and, 60, 797, 886-887, 924
 - polyunsaturated fatty acids and, 59, 62-63, 427, 434, 455, 492, 770, 798-799, 820-821, 826-831
 - pregnancy, 389
 - protein and, 60
 - prothrombotic markers, 799, 802
 - randomized controlled clinical trials, 828-829
 - risk factors, 57, 563
 - saturated fatty acids and, 422, 481-484, 797, 798, 799
 - sugar intake and, 303, 800-801
 - trans* fatty acids and, 58, 423, 504, 510-513
 - tricylglycerol and, 57-58, 59, 437
 - Cortisol, 189, 715
 - Creatine/creatinine, 603, 604, 607, 608, 609, 620, 647, 684, 697, 842
 - Critical endpoints, 93, 98, 99, 101, 102
 - Cysteine/cystine (dispensable), 589, 591, 592, 593, 594, 601, 607, 608, 614, 663-665, 666, 668, 672-675, 677, 678, 679-682, 683, 685, 686, 687, 689, 711-712, 736, 998-999
- D**
- Data and database issues
 - adjustments to survey data, 49-50
 - critical data set, 98
 - dietary intake data, 49-50, 117
 - for dose-response assessment, 98, 101-103
 - quality and completeness of data, 2-3, 40, 43, 44, 46, 85, 86, 90, 97, 99, 180, 479, 969
 - research needs, 969-971
 - selection for dose-response assessment, 90, 98
 - statistical analysis, 612-613
 - uncertainties in, 86, 99, 1246
 - validation of dietary intake data with, 117
 - Dehydration, 926-927
 - Dental caries, 61-62, 296-297, 323
 - Department of Health Survey of British School Children, 307-310, 314-317, 792-793
 - Depletion-repletion studies, 40-41
 - Dermal effects of amino acids, 733-734, 735
 - Dermatitis, 5, 442, 444, 460
 - Developmental effects. *See also* Growth and development
 - of amino acids, 708-710, 724, 732
 - of functional fiber, 396
 - of *n*-3 polyunsaturated fatty acid deficiency, 444-447
 - Dextrose, 295
 - Diabetes mellitus, type 1, 268, 275
 - Diabetes mellitus, type 2
 - adults, 268, 388, 784-785
 - and amino acids, 704
 - BMI and, 124, 226-229
 - carbohydrate intake and, 63, 302, 303, 306-307, 785
 - cholesterolemia intake and, 563
 - epidemiological studies, 380-381, 785, 803, 832
 - fat intake and, 62-63, 437-438, 460, 802-808
 - fiber intake and, 63, 352-353, 354, 355, 359-360, 380-382, 388
 - gender differences, 380, 381
 - genetic factors, 62
 - glycemic index and, 63, 302, 304-307, 308-309, 322
 - glycemic response, 268, 271
 - HDL cholesterol and, 308-309
 - high fat, low carbohydrate diets and, 802-808
 - insulin resistance, 63, 275, 303, 306-307, 308-312, 784-785
 - intervention studies, 381-382, 785, 786-787, 806-807, 832-833
 - lipid profile, 308-309
 - low fat, high carbohydrate diets and, 437-438, 772, 784-785
 - monounsaturated fatty acids and, 819
 - obesity and overweight and, 802, 803
 - physical activity and, 63-64
 - polyunsaturated fatty acids and, 494, 821, 832-833
 - protective effects of nutrients, 380-381
 - risk factors, 57, 62, 563
 - saturated fatty acids and, 484-485
 - sugar intakes and, 303

- Diabetes Prevention Program Research Group, 806-807
- Dialysis, 722
- Diammonium citrate, 594
- Diarrhea, 397, 398, 438, 693
- Diet and Reinfarction Trial (DART), 828
- Dietary and Nutritional Survey of British Adults, 314-315, 316-317, 318-319
- Dietary Approaches to Stop Hypertension diet, 798
- Dietary intakes. *See also individual nutrients*
- adjustment of data, 49-50, 103, 938, 941-942, 943
 - assessment of, 88-89, 90, 118, 323, 436 and bioavailability, 940, 944
 - breast-fed infants, 45, 624, 939-940
 - Canadian, 1066-1075
 - and chronic disease, 970
 - corroboration of, 437
 - day-to-day variations in, 49, 938, 940, 941-942, 943
 - energy density of foods and, 794-796
 - food composition databases, 48, 49-50, 941
 - food frequency questionnaires, 939
 - food quotient from, 120
 - form of, 96 n.2
 - gender differences, 265, 294, 473, 474, 692, 988-1065
 - menu samples, 392-393
 - methodological issues, 42, 48, 49-50, 110, 116, 117-118, 307, 312, 313, 322, 563, 624, 643, 936-937
 - self-reported, 42, 48-49, 64, 117-118, 307, 479, 938
 - sources of data, 49-50
 - underreporting, 42, 49, 110, 117-118, 313, 643, 794, 936-937, 944, 956
 - using data from, 937-939, 940
- Dietary Intervention Study in Children (DISC), 812, 814
- Dietary Reference Intakes (DRIs)
- applicable population, 30, 202
 - assessment applications, 16-18, 23-24, 936, 937-941
 - categories, 2, 22-28; *See also* Acceptable Macronutrient Distribution Ranges; Adequate Intakes; Estimated Average Requirements; Recommended Dietary Allowance; Tolerable Upper Intake Levels
 - criteria for, 3, 5-13, 21-22, 44
 - defined, 2, 3, 21-22
 - extrapolation from other age groups, 26-27, 31-32, 34, 101, 982-984
 - framework, 36, 979-981
 - group applications, 16-18, 23-24, 941-945, 947-949
 - individual applications, 26, 30, 937-941, 946
 - origin, 978-979
 - parameters for, 29-36; *See also* Life-stage groups; Reference weights and heights
 - planning applications, 24, 936, 946-949
 - rationale for, 1, 978-979
 - sources of data, 2-3, 36, 43-44; *See also* Methodological considerations
 - uses, 16-18, 28, 936-966
 - WHO/FAO/WHO approach compared, 24
- Direct amino acid oxidation (DAAO)
- method, 615-617, 618, 619, 670-671, 676-678
- Disaccharides, 265, 266, 272, 281, 342
- Diverticular disease, 371-372, 388
- Docosahexanoic acid (DHA), 9, 55, 59, 62, 427, 435, 439, 440, 443, 444-446, 447, 453, 455-456, 466, 468, 469, 470, 471, 472, 478, 487, 492, 494, 770, 826, 828, 829, 833, 1056-1057
- Docosapentaenoic acid, 426, 427, 1054-1055
- Dose-response assessment. *See also individual nutrients*
- animal studies, 96, 98, 100
 - components and process, 87-88, 95
 - critical endpoint, 93, 98, 99, 101, 102
 - data quality and completeness, 98, 101-103
 - data selection, 90, 98
 - defined, 974
 - derivation of UL, 90, 98, 101
 - human studies, 98
 - LOAEL/NOAEL identification, 90, 98, 99-100, 102
 - special considerations, 100, 101
 - uncertainty assessment, 98, 100-101
- Doubly labeled water method
- advantages, 120
 - BEE predictions, 1104-1202
 - data analysis and assumptions for equations, 43, 154-157, 183

description of database, 151-157
 EAR determination, 47
 factorial method compared, 119
 inclusion/exclusion criteria, 152-154
 methodological issues, 120-121, 152, 198
 normative database, 151-153, 154-155
 overweight and obese database, 153, 156-157
 prediction equations, 154-157
 pregnant women, 193, 196-197, 290
 representativeness of sample, 152
 statistical analysis of studies, 43
 TEE predictions, 116, 117, 119-121, 122-123, 138-139, 141, 151-157, 166, 174, 193, 198-199, 201, 291, 1104-1202
 validation of dietary intake data with, 117
 whole-body calorimetry results compared, 120, 122-123
 Duodenal ulcer, 370, 372

E

Eating behavior
 amino acid supplementation and, 707, 709, 710, 713, 730, 731-732
 appetite sensations and, 795
 cognitive factors, 796
 energy density of foods and, 794-796
 palatability of foods and, 795, 809
 Eating disorders, 928
 Eicosanoic acid, 426
 Eicosanoids
 metabolism, 9, 55, 423, 434, 454, 825, 833, 838
 proinflammatory, 59
 Eicosapentanoic acid (EPA), 9, 55, 59, 62, 427, 435, 439, 443, 453-454, 460, 466, 469, 470, 471-472, 478, 487, 492-493, 494, 770, 826, 828, 829, 832, 833, 1052-1053
 Eicosatrienoic acid, 439, 440, 442
 Elaidic acid, 427, 436, 495
 Endometrial cancer, 56, 57, 379, 844
 Endorphins, 916
 Endothelial function, 59
 Energy balance, 107, 111-112, 164
 adaptation, 149-151, 201, 220, 223-224, 452
 negative, 213-215
 physical activity and, 4, 5, 57, 65, 116, 138, 143, 157-161, 184, 221-223, 452, 884-912
 research recommendations, 225, 240, 323-324
 and weight, 65, 150, 212, 214, 220
 Energy density of foods and, 64, 794-796
 Energy expenditure. *See also* Basal energy expenditure; Resting energy expenditure; Total energy expenditure; *individual life-stage groups*
 age/aging and, 117, 143-144, 157, 158, 159-161, 181, 183
 altitude and, 149
 BMR and, 112-114, 115, 131, 141, 164-165, 171, 178-179, 185, 188-190, 195
 body composition and size and, 65, 112, 131-135, 138, 139, 141
 climate and, 147-148
 environment and, 147-148, 149
 ethnicity and, 145-146
 factors affecting, 131-151, 165
 gender differences, 108, 114, 132, 140-141, 143, 148, 157, 158, 217
 genetics and, 144-145
 and growth rate, 134, 164, 190-192
 height and, 157, 159-161
 lactation and, 116, 198-199
 measurement of, 118-121, 122-123, 140
 obesity and overweight and, 111, 122-123, 133-135, 138, 140, 209, 212, 216-219
 of physical activity (EEPA), 115-116, 117, 133, 138-140, 141, 143-144, 145-146, 147, 183, 190, 209, 212, 884-913
 postexercise, 139
 pregnancy, 189, 193
 research recommendations, 225, 240
 RMR and, 112, 131, 132, 141, 148, 165
 TEF and, 114, 115, 116, 150, 165, 171
 and thermoregulation, 114
 weight and, 132, 135, 141, 150, 159-161, 183, 184, 186, 206-213, 215, 889, 891-895, 951
 Energy intake. *See also* Acceptable Macronutrient Distribution Ranges; *individual macronutrients and life-stage groups*
 adaptation to, 149-151, 201, 220, 223-224, 452

- adverse effects of overconsumption, 54, 57, 110, 223-239
- alcohol contribution, 109, 771, 1064-1065
- assessment, 48, 225, 954-956
- Canada, 1066-1075
- and cancer, 54
- energy density of foods and, 64, 794-796
- environment and, 150
- FAO/WHO/UNU recommendations, 170
- and glycemic index of foods, 269, 313, 320, 322
- for groups, 952-954, 955-956
- hazard identification, 223-224
- indicators of adequacy or inadequacy, 110-111
- of individuals, 949-952, 955
- interrelationships of nutrients, 39, 103, 770-771, 964
- intra-individual variability, 111
- by life stage and gender group, 1028-1031, 1034-1035, 1040-1041, 1062-1067, 1072-1075
- and obesity, 54, 65, 111, 307, 310, 312, 313, 322, 794
- planning, 949-954, 963
- research recommendations, 225
- restricted, 54
- sugar contribution, 65, 118, 273, 307, 310, 313, 314-315, 770
- total, 1034-1035
- underreporting, 42, 49, 117-118, 643, 794, 956
- and weight, 223-224, 793-794, 951-952
- yields from substrates, 108-110
- Energy metabolism, 289
- Energy mobilization from tissues, 199-200
- Energy requirements. *See also* Estimated Energy Requirements
 - accommodation, 151
 - adaptation, 150
 - age/aging and, 183, 647
 - athletes, 221-223
 - BMI and, 121, 124-131
 - BMR and, 164-165, 171, 178-179, 185, 188-190, 195-196
 - brain, 278
 - climate and, 146-147, 149
 - environment and, 146-147
 - factors affecting, 131-151
 - FAO/WHO/UNU criteria, 111-112
 - genetics and, 144
 - for growth, 45, 116-117, 142, 166-168, 174, 177, 181, 190-192, 441
 - measurement, 160-161
 - nutrient requirements compared, 110-111
 - obesity and overweight and, 110, 132-133, 135, 138, 202-213, 216-219
 - physical activity and, 38, 138-140, 157-161, 166, 171, 174, 175, 176-181, 182, 183-184, 190, 197-198
 - pregnancy, 290
 - research recommendations, 225
 - restoration of normal weight, 220-221
 - special considerations, 202-223
 - TEF and, 165, 171, 190, 196-197
 - thermoregulation and, 165-166
 - total, 200-201
 - weight and, 112, 183, 184, 220
- Environment
 - altitude, 149
 - climate, 146-149
 - and energy expenditure and requirements, 146-149
- Eosinophilia-myalgia syndrome (EMS), 733
- Eosinophilic fasciitis, 733, 734
- Epidemiological studies. *See also* Observational studies
 - analytic studies, 41, 42
 - breast cancer, 54
 - carbohydrates, 783, 785, 800-801
 - CHD, 362-365, 562-569, 797-798, 800-801, 817, 820-821, 826-828
 - cholesterol, 562-569
 - colon cancer, 373-374
 - diabetes risk, 380-381, 785, 803, 832
 - fiber and disease prevention, 343-344, 362-365, 368, 373-374, 380-381, 382-383
 - glucose metabolism, 380-381
 - hazard identification, 95, 96
 - high fat, low carbohydrate diets, 792-794, 797-798, 803
 - hyperlipidemia prevention, 362-365
 - hypertension prevention, 362-365
 - insulin sensitivity, 380-381
 - limitations, 41, 42, 95, 322
 - low fat, high carbohydrate diets, 783, 785
 - methodological issues, 40, 41-42, 322, 569
 - monounsaturated fatty acids, 817

- obesity risk, 792-794, 796-797
 physical activity, 912-917
 polyunsaturated fatty acids, 820-821, 826-828, 832
 satiety and weight maintenance, 382-383
 sugar and chronic disease, 800-801
trans fatty acids, 510-515
- Esophageal cancer, 844
- Estimated Average Requirements (EARs).
See also individual nutrients and life-stage groups
 coefficient of variation, 24-25
 cut-point method, 943, 952
 data quality and completeness, 969
 defined, 3, 22-23
 derivation of, 28, 34, 47, 631
 evidence considered for, 46-47, 277-280, 284, 285-293, 646-648, 656-659, 664-669
 extrapolation on body-weight basis, 34, 44, 45, 47
 factorial method, 631
 indicators of adequacy, 6, 28, 110
 method used to set, 23, 46-47, 624-629, 635, 637-639, 666-669, 681-682, 981-982
 prevalence of intakes below, 789
 and RDA, 23, 24
 reported energy intakes and, 117-118
 standard deviation, 24-25, 629
 uses, 23-24, 688, 936, 938-939, 943-944, 947-948
- Estimated Energy Requirements (EERs). *See also Energy requirements; individual life-stage groups*
 averaging for group members, 953-954
 criteria for, 5
 defined, 3, 4, 22, 107, 202
 derivation of, 107, 116-117, 168-170, 174-177, 181-182, 184-185, 193-197, 201-203
 evidence considered in determining, 116, 164-168, 171-174, 177-181, 183-184, 185, 188-193, 195-201
 gender differences, 169-170, 176-179, 185, 202-203
 indicator selection for, 117-131
 by life stage and gender group, 5, 164-223
 menu samples, 392-393
 methodological issues, 202-203
 for reference person, 952-953
 special considerations, 30, 202-223
 TEE and, 149-150, 166, 168-169, 174, 176, 181, 183, 188, 193, 200-201, 202, 208
 uses, 951, 952-953
- Estrogen, 56, 378-380, 543, 921
- Ethanolamine phosphoglycerides, 435
- Ethnicity. *See Race/ethnicity; individual ethnic groups*
- EURAMIC study, 827
- European Center Prevention Organization Study, 398
- Excretion. *See also individual nutrients*
- Explorers, high-protein diets, 693
- Exposure
 acceptable or tolerable, 86-87
 assessment, 88-89, 90
 duration of, 96, 99
 route of, 96, 98, 713
- ## F
- Factor VII activity, 369, 799
- Factorial approach, 25, 118-119
 amino acids, 614, 666-669
 children, 628, 631, 666-669
 DLW method compared, 119
 PAL evaluation, 118, 899-902
 protein, 610-611
 TEE, 116
- Fat (dietary), total. *See also Fatty acids; High fat; Lipids and lipid metabolism; Low fat; Phospholipids; Triacylglycerol or triacylglyceride*
 absorption, 4, 60, 339, 351-352, 369, 375, 429, 442, 447, 450-452
 adaptation to, 452
 adverse effects of, 58, 481
 AIs, 4, 9, 32, 456-457
 and alcohol metabolism, 453
 AMDRs, 15, 422, 423, 440, 481, 769, 785, 809, 816, 945
 animal studies, 40
 assessment of intakes, 959
 balance, 441, 452
 and bioavailability of vitamins, 424, 785, 788-792
 and BMI, 814
 and cancer, 54-55, 371, 375, 376, 484, 486, 512-515, 808

- carbohydrate ratio, 437
- and CHD, 58-59, 437-438, 460, 769, 797-799, 802
- and chronic disease risk, 437-438, 460
- and diabetes type 2, 62-63, 437-438, 460, 802-808
- dietary intakes, 46, 49, 64, 118, 457, 473, 959, 1038-1041, 1070-1071, 1226-1227
- energy contribution, 64, 109, 424, 430, 437, 441, 473, 769, 771, 814, 1040-1041, 1070-1071, 1226-1227
- evidence considered for estimating requirements, 440-441
- excretion, 431, 447
- factors affecting requirements, 447, 450-452
- fiber and, 4, 351-352, 367, 369, 375, 376, 808
- food sources, 48, 54, 280, 424, 448-451, 457, 473
- function, 4, 38, 424-425
- gastric emptying, 438
- gender differences, 473
- genetic factors, 452
- and glucose intolerance, 802-808
- and glycemic index of foods, 269
- glycerol metabolism, 289, 430, 784-785, 802-909
- and growth, 280, 437, 441, 457, 459
- high fat diets, 452, 769, 772, 792-810
- inadequate intakes, 437-438
- and insulin sensitivity, 62, 303, 430, 437, 438, 802-808
- intervention studies, 64, 794-796
- by life stage and gender group, 9, 456-460, 1038-1039, 1040-1041, 1070-1071
- and lipid profile, 58, 429, 437, 483, 544, 550-559, 560, 777-782, 809, 815
- low fat diets, 359, 366, 375, 378-379, 438, 442, 772-792
- malabsorption, 442, 452
- and metabolic syndrome, 802
- and micronutrient intakes, 808-809, 816
- and obesity, 64, 459, 460, 772, 773-776, 792-797, 802, 803, 814
- oxidation, 452, 810, 832, 922
- physical activity and, 430, 452, 773
- planning intakes, 959
- polyunsaturated intake and, 58
- protein and, 60, 271, 693
- research recommendations, 324, 505, 514
- saturated fat intake and, 58, 799
- special considerations, 457
- stores, 595; *See also* Body fat
- TEF, 114
- and weight, 441, 452, 773-776, 809
- Fat-free mass
 - energy expenditure and, 112, 113, 128, 131, 186, 212
 - height and, 125, 128-130
 - measurement, 121
 - and metabolic rate, 131, 139
 - physical activity and, 139, 923
 - and protein status, 609
 - puberty and, 142
- Fat mass, 121, 125, 128-130, 142, 814, 923
- Fat-soluble vitamins, 94
- Fatigue, 706, 733, 920
- Fatty acids. *See also* Fat, total;
 - Monounsaturated fatty acids;
 - Polyunsaturated fatty acids; Saturated fatty acids, *n*-3; *Trans* fatty acids
- alcohol consumption and, 453
- from carbohydrates, 275, 277, 433
- categories, 424
- dietary intakes, 1228-1243
- energy contribution, 349, 1228-1243
- from fiber, 348, 361, 371, 372
- food sources, 48
- function, 38, 424-425
- integrated dietary planning, 964
- metabolism, 189, 275, 277, 348, 361, 371, 372, 425, 430-431, 453
- oxidation, 166, 279, 430, 432, 440, 453, 920
- storage, 430
- transport, 429, 430, 432
- Federation of American Societies for Experimental Biology, 713, 716
- FELS Longitudinal Study, 174, 181
- Female athlete triad, 928
- Fetus
 - amino acids, 708-709, 732
 - congenital defects, 728
 - energy cost of tissue deposition, 190-192
 - energy expenditure, 185, 437
 - fatty acid metabolism, 433, 436, 445
 - glucose metabolism, 189-190, 290-292, 910
 - hypoxemia, 910
 - intrauterine growth delay, 728
 - neural tube defects, 726
 - protein, 839

- Fiber, dietary or functional, 957-958. *See also individual sources of fiber*
- absorption, metabolism and excretion, 348-349
 - adverse effects of, 377, 391-395
 - allergic reactions, 396, 397, 399
 - animal studies, 351, 361, 377
 - and appetite, 383
 - and *Bacteriodes*, 357
 - between-country studies, 377-378
 - and *Bifidobacteria*, 354
 - and BMI, 352, 379, 383, 384
 - C-peptide response, 353, 361
 - Canadian guidelines, 340, 349
 - and cancer, 54, 55-56, 319, 321, 339, 348, 373-380, 396, 398
 - case-control studies, 378
 - characteristics, 341-342
 - and CHD, 59-60, 322, 339, 356, 362-368, 369, 387-388, 389, 563
 - clinical effects of inadequate intake, 361-362
 - and colon health, 55-56, 321, 339, 348, 358, 370-377, 385-386, 388
 - definitions, 4, 339, 340-341, 342-343
 - description of, 344-347
 - developmental effects, 396
 - and diabetes type 2, 63, 352-353, 354, 355, 359-360, 380-382, 388
 - dietary, 4, 339, 340-343, 344, 345, 346, 347, 348, 349, 355, 361-369, 370-384, 385-387, 390, 391, 394-395, 771, 788, 808, 838
 - diverticular disease prevention, 371-372, 388
 - and duodenal ulcer, 370, 372
 - energy contribution, 348, 349, 371, 372, 383, 385, 386, 388, 788
 - epidemiological studies, 343-344, 362-365, 368, 373-374, 380-381, 382-383
 - and estrogen, 56, 378-380
 - evidence considered for estimating requirement for, 362-384
 - examples of, 343
 - and fat absorption, 4, 339, 351-352, 367, 369, 375, 376
 - fatty acid metabolism, 348, 361, 371, 372
 - fermentation of, 56, 348, 355, 371, 372, 375
 - function, 38
 - functional, 4, 339, 340, 341, 342, 343-344, 345, 346-347, 348-350, 355, 369, 361-362, 365, 366, 367, 369, 370, 371, 372, 374, 377, 379, 382, 388, 391, 395-399
 - and gastric emptying, 4, 63, 65, 339, 348, 360, 370, 379, 382, 383
 - and gastrointestinal health, 348, 350, 351, 352, 353-354, 355, 356, 357-358, 360-361, 370-372, 396-397, 398, 839
 - genotoxicity, 396
 - glucose response, 63, 339, 350, 351, 352-353, 354, 355-356, 357, 359-360, 361, 380-382, 383, 388
 - and glycemic index of foods, 322, 360, 361, 380-381, 382
 - hazard identification for, 395-399
 - health benefits, 343
 - high fat diets and, 808
 - high-fiber diets, 297, 374, 378-379, 383, 788, 839
 - and hyperlipidemia prevention, 355, 362-368
 - and hypertension, 60, 362-368, 369
 - insulin response, 60, 63, 297, 306-307, 339, 351, 353, 355-356, 360, 380-382, 388
 - intervention studies, 344, 351, 358, 365-368, 374-377, 378-379, 381-382, 383-384
 - and *Lactobacillus*, 357
 - and laxation, 339, 350, 351, 352, 353-354, 355, 356, 357-358, 360-361, 370-371, 372, 385-386, 388
 - and lipid metabolism, 297, 350, 351, 352, 354, 355, 356-357, 358-359, 360, 361, 365-366, 388
 - and lipid profile, 4, 59-60, 339, 351, 352, 354, 355, 356, 357, 358-359, 360, 361, 365-368
 - low-fiber diets, 367, 838
 - measures of efficacy, 344, 350
 - methodological problems with trials, 376-377
 - and micronutrient absorption, 4, 29, 94, 348, 351-352, 369, 382, 391, 394-395, 397-398, 838
 - nutrition labeling, 340, 344
 - and obesity, 65, 352, 370, 382-384
 - physiological role, 343, 349-361
 - properties, 339

- prospective studies, 378
 - protective effects, 55-56, 59, 63, 322, 339, 348, 363, 367-368, 369, 372, 374, 375, 376-380
 - research recommendations, 399-400
 - and satiety, 65, 348, 382-384, 388
 - sources, 48, 56, 341-342, 344, 349, 350, 390, 771
 - special considerations, 395
 - supplements, 60, 361, 365, 366, 370, 371, 372, 374, 383, 394, 398
 - synthetic fibers, 342, 349-351
 - USDA database, 344, 346
 - and water intake, 398
 - and weight control, 65, 339, 351-352, 370, 382-384
 - Fiber, total (dietary + functional)
 - AIs, 4, 7-8, 322, 339, 369, 372, 384-385, 386, 389-390, 944-945
 - and cancer, 56, 373
 - definition, 4, 339, 340
 - and diabetes type 2, 382
 - dietary intakes, 339, 387, 391, 392-393, 1036-1037, 1226-1227
 - expression of requirement, 384-385
 - by life stage and gender group, 7-8, 384-390, 1036-1037
 - menu samples, 392-393
 - planning intakes, 957-958, 964
 - Fibrinolysis, 60
 - Fish and fish oil, 55, 59, 826-828, 832
 - Fluoride, 297
 - Folate/folic acid, 375, 726, 789, 790-791, 808, 812, 816, 1228-1243
 - Food. *See also* Thermic effect of food
 - additives, 90, 350, 366, 391
 - allergies, 692
 - amino acid composition, 683-686, 689-690
 - energy-dense, nutrient-poor, 302, 312, 794-796
 - palatability, 425, 795, 808, 809
 - plant- vs. animal-derived, 771
 - safety, 86-90, 104
 - supplementation trials, 654
 - Food and Agriculture Organization, 84, 110, 621, 634, 648, 684
 - Food Guide Pyramid, 266, 267, 391, 771
 - Food quotient, 119-120
 - Food sources. *See also individual nutrients*
 - determination of, 50
 - Formulas, infant
 - amino acids, 731, 733
 - bioavailability of nutrients from, 26, 31, 45, 431, 940, 944, 946
 - carbohydrates, 280, 283
 - cholesterol, 545, 548-549
 - FAO/WHO/UNU recommendations, 621
 - fat (total), 280-281, 448-451, 457
 - fatty acids, 461, 463, 466, 468, 479
 - protein, 280-281, 621
 - Fortified foods, 27, 85, 91-92. *See also* Formulas, infant
 - Fructans (dietary or functional fiber), 341, 342
 - Fructooligosaccharides (dietary or functional fiber), 345-346, 353-354, 396-397, 838
 - Fructosamine, 304-307
 - Fructose, 59, 266, 267, 268, 273, 274, 276, 294, 295, 297, 298-301, 302, 809, 813
 - Fructose-1-phosphate aldolase deficiency, 809
 - Fruits and vegetables, fiber and, 56, 363, 371, 373, 374, 375, 378, 388, 394, 788
- ## G
- Galactomannans, 345, 352
 - Galactose, 266, 273-274, 276, 281
 - Galacturonic acid, 345
 - Gallbladder disease, 234-235
 - γ -Linoleic acid, 426, 446, 476, 477, 824
 - Gastric emptying
 - amino acids, 615
 - energy density of food and, 795
 - fat, 438
 - fiber and, 4, 63, 65, 339, 348, 360, 370, 379, 382, 383
 - Gastrointestinal distress, fiber intake and, 394-395, 396-397, 398
 - Gastrointestinal health
 - amino acid supplementation and, 698, 700, 714, 720, 722, 724, 726, 733
 - fiber and, 348, 350, 351, 352, 353-354, 355, 356, 357-358, 360-361, 370-372, 396-397, 398, 839
 - protein intake and, 844
 - Gender differences. *See also* Men; Women
 - added sugars, 988-991
 - amino acids, 673-675, 732, 992-1027

- BMI, 125-129, 1078-1087, 1098-1103
 body composition and size, 128, 142, 1078-1103
 body fat, 1078-1101
 and carbohydrate–lipid oxidation
 balance, 921
 cardiovascular disease, 60
 dietary intakes, 265, 294, 473, 474, 692, 988-1065
 EER, 169-170
 energy expenditure, 108, 114, 132, 140-141, 143, 148, 157, 158, 217
 energy intake, 473
 fat (dietary), 473
 fiber, 386, 387, 389, 391
 growth velocity, 33, 142, 175, 922-923
 linoleic acid, 463-464
 metabolic rate, 141
 monounsaturated fatty acids, 474
 nutrient intakes with added sugars, 1203-1225
 physical activity, 921
 polyunsaturated fatty acids, 8, 463-464, 470, 471, 478
 protective effects of nutrients, 60
 puberty onset, 33
 reporting of dietary intakes, 117
 saturated fatty acids, 474
 weight and heights, reference, 35
- Genetic factors
 body composition and size, 144, 146
 cancer, 55
 CHD, 57
 cholesterol, 58, 544, 545, 546, 561-562
 diabetes mellitus, type 2, 62
 energy expenditure, 144-145
 energy requirements, 144
 fat balance, 452
 obesity, 146, 452, 784
- Genetic markers of disease, 41
- Genotoxicity, 396, 720
- Glucagon, 189, 277
- Glucated hemoglobin (HbA_{1c}), 308-309, 322
- Glucoamylase, 272
- Glucocorticoids, 602
- Gluconeogenesis
 amino acids and, 276, 278, 288-289, 604, 606
 carbohydrate-free diet and, 275-276, 277, 287-288
 energy cost of, 114
 glycerol from fat and, 278-279, 289, 292-293, 430
 in infants, 280
 insulin and, 274
 pregnancy and, 189
 protein and, 278, 284, 287-288, 293
 starvation and, 277
- Glucoregulatory hormones, 57
- Glucose, 266, 345
 in human milk, 282-283
 intestinal absorption, 63, 273, 383
 transporters, 273
- Glucose–alanine cycle, 607
- Glucose–glutamine, 607
- Glucose metabolism. *See also*
 Gluconeogenesis; Insulin response
 adaptation, 277-278
 adolescents, 288-289
 adults, 285-289, 388, 784-785
 altitude and, 149
 for brain utilization, 38, 265, 273, 276, 277, 279-280, 285-289
 children, 286-287, 288-289
 energy yields, 109, 274
 epidemiological studies, 380-381
 fat intake and, 289, 430, 784-785, 802-909
 fiber and, 63, 339, 350, 351, 352-353, 354, 355-356, 357, 359-360, 361, 380-382, 383, 388
 glycemic index of foods and, 63, 268, 306, 322
 high fat, low carbohydrate diets and, 437, 802-808
 infants, 280, 281, 288-289
 intervention studies, 381-382
 intracellular utilization, 274
 lactation and, 196
 and lipogenesis, 59
 low fat, high carbohydrate diets and, 438, 784-785
 and ketosis, 276, 277, 278-279, 280, 281, 284, 287, 289, 290-291, 430
 methodological issues, 280
 monounsaturated fatty acids and, 819
 muscle uptake, 63, 430
 obesity and, 204, 802
 physical activity and, 60, 921
 polyunsaturated fatty acids and, 821, 822-823

- pregnancy and, 189-190
- and protein requirement, 278, 605
- saturated fatty acids and, 484-485
- weight loss and, 204
- Glutamate, 591, 593, 594, 596, 604, 605, 606, 608, 697, 701, 703, 709, 712, 717. *See also* Monosodium glutamate
- Glutamic acid (dispensable), 592, 593, 594, 596, 597, 712-718, 728, 736, 1000-1001
- Glutaminase, 717
- Glutamine (dispensable), 591, 593, 594, 596, 605, 607, 706, 717-719
- Glutamine synthetase, 717
- Glutathione, 607, 608, 620
- Glycemic index (GI), 321-323
 - amount of food ingested and, 268
 - and BMI, 313
 - calculation, 268, 307
 - and cancer risk, 310-311, 319, 321
 - and carbohydrate metabolism, 304-307
 - and CHD risk, 303, 308-311, 322
 - definition, 268
 - and diabetes type 2, 63, 302, 304-307, 308-309, 322
 - digestability of foods and, 269
 - and energy intake, 269, 313, 320, 322
 - fiber and, 322, 360, 361, 380-381, 382
 - food characteristics and, 269-270
 - food values, 268, 270
 - and glucated hemoglobin (HbA_{1c}), 308-309, 322
 - and glucose metabolism, 63, 268, 306, 322
 - and HDL cholesterol, 308-309, 322
 - high-GI diets, 302, 306-307, 313, 318, 323
 - and hunger and satiety, 313
 - and insulin sensitivity, 63, 306-307, 308-312, 322
 - and lipid metabolism, 269, 270-271, 297, 302-303, 304-308, 322
 - low-GI diets, 304-307, 313, 321-322
 - of mixed meals, 270-271
 - methodological issues, 322
 - and obesity, 313, 322-323
 - palatability of foods and, 272
 - and physical activity, 318-319
 - utilization, 269-272
 - and weight loss, 313
- Glycemic load, 269-272, 303, 322, 380-381
- Glycemic response, 63, 268, 322
 - of diabetics, 268, 271
 - to fiber, 63, 352
 - palatability of foods and, 795
- Glyceraldehyde, 274
- Glycerol, 289, 292-293. *See also* Triacylglycerol or triacylglyceride
- Glycine (dispensable), 591, 593, 596, 597, 607, 608, 678, 719-720, 729, 731, 736, 1002-1003
- Glycogen
 - amino acids and, 705
 - food sources, 265-266
 - repletion, 64, 924
 - storage, 273, 276, 281, 595-596
 - synthesis and utilization, 274, 277, 920, 921, 923
- Glycoprotein, 692
- Glycolysis-tricarboxylic acid (TCA) pathway, 605, 606
- Greenland Eskimos, 275, 284, 493, 494, 826
- Growth and development. *See also individual life-stage groups*
 - adaptation, 151, 220, 437
 - amino acids and, 598, 607, 665, 666, 669, 697, 701, 707, 710, 713, 719, 720, 721, 724, 725, 728
 - carbohydrates and, 280-281, 922-923
 - catch-up in children, 221, 222, 840
 - children, 32, 47, 134, 142, 151, 167-168, 174, 175, 221, 222, 437, 441, 456, 459, 609, 611, 810-811, 839-840
 - defined, 177
 - and EAR derivation, 47
 - and EER derivation, 116, 166-168, 174, 181
 - energy expenditure and, 134, 164, 190-192
 - energy requirements, 45, 116-117, 142, 166-168, 174, 177, 181, 190-192, 441
 - fat intake and, 280, 437, 441, 457, 459
 - formula-fed infants, 280-281, 448-451, 457
 - gender differences, 33, 142, 175, 922-923
 - impaired, 151, 217, 220, 221, 222, 437, 721, 811, 839-840
 - lipid metabolism, 922-923
 - low fat, high carbohydrate diets and, 810-811
 - maternal and fetal tissues, 92, 190-192
 - measurement precision, 142
 - physical activity and, 922-923

polyunsaturated fatty acids and, 444-447, 453, 460
 protein intake and, 280-281, 608-609, 654, 683, 811, 839-840
 puberty and, 142, 922
 stunting, 151, 217, 220, 221, 222, 811, 840
 undernutrition and, 220, 221, 222
 velocity, 33, 47, 142, 151, 166-168, 181
 Growth hormone, 277, 699, 715, 724, 923
 Guar gum, 63, 352-353, 355-356, 365, 366, 382, 396
 Gums (dietary or functional fiber), 345, 355, 365, 367, 369, 388, 391, 396. *See also* Guar gum

H

Hawaiian natives, 798
 Hazard identification. *See also individual nutrients*
 animal data, 94-95, 96, 696, 697-698, 701-702, 707-708, 711-712, 713-714, 721-722, 724, 725-726, 727, 729, 730-732, 734-735
 asthma, 716-717
 behavior, 295-296
 cancer, 319-321
 causality, 94, 96, 102
 Chinese restaurant syndrome, 715-716
 components of, 87, 94-98
 data sources, 96-97
 defined, 87, 975
 dental caries, 296-297
 developmental studies, 708-710
 diabetes, 303, 306-307
 evaluation process, 95
 human studies, 94, 696, 698-699, 702-703, 705-706, 712, 714-715, 722-723, 724-725, 726, 727, 729, 730, 732-733, 735
 insulin sensitivity, 303, 306-307
 maple syrup urine disease, 706
 metabolic considerations, 705
 obesity, 307, 311-313, 314-319
 pharmacokinetic and metabolic data, 96-97, 98
 physical activity, 318-319
 HDL cholesterol. *See also* Lipids and lipid metabolism
 carbohydrate intake and, 59, 781-784

and CHD, 57
 cholesterol intake and, 549-562, 563, 568-569
 in diabetes, 308-309
 fat intake and, 437, 483, 777-782
 fiber intake and, 354, 357, 358, 359, 361, 366
 glycemic index and, 302, 303, 308-309, 322
 hazard identification, 549, 560-562
 lipoprotein lipase activity and, 61
 low fat, high carbohydrate diets and, 777-781
 monounsaturated fatty acid intake and, 817-818
 physical exercise and, 60, 61
 polyunsaturated fatty acids and, 820, 821, 822-823, 826, 828, 830-831
 protective effect, 560
 saturated fatty acids and, 483
 sugar intake and, 298-301, 302
 trans fatty acids and, 495-503
 transport, 543, 544
 Health Canada, 349, 481, 883, 979
 Health Professionals Follow-Up Study, 321, 363, 364, 368, 371-372, 375-376, 377, 387, 562, 563, 827
Healthy People 2000, 882
 Heart disease. *See also* Cardiovascular disease; Coronary heart disease
 carbohydrate intake and, 59
 fiber intake and, 59-60
 physical activity and, 60-61
 protein intake and, 60
 Heat of combustion, 108, 109
 Height. *See also* Reference weights and heights
 BMI and, 1080-1081
 and body composition, 125, 128-130, 1078-1081, 1088-1089
 catch-up growth, 221
 and energy expenditure, 157, 159-161
 Heme, 607, 608
 Hemicelluloses (dietary fiber), 345, 348, 390
 Hemoglobin, 595, 720-721
 Hepatic lipase activity, 61
 Hepatomegaly, 721
 Heterocyclic amines, 379
 High fat, high carbohydrate diet, 367
 High fat, high protein diet, 275

- High fat, low carbohydrate diets, 103
 added sugars, 810, 816
 adults, 792-810
 AMDRs, 809, 816
 cancer risk, 808
 CHD risk, 797-802, 814-815
 children, 814-816
 diabetes (type 2) risk, 802-808
 energy intakes, 793-795
 epidemiological studies, 792-794, 797-798, 803
 fat excess, 808-809
 and glucose intolerance, 437, 802-808
 hyperinsulinemia, 802-808
 intervention studies, 794-796, 798-799, 803-807
 metabolic syndrome, 802-808
 and micronutrient inadequacy or excess, 808-809, 816
 obesity risk, 792-797, 814
 saturated fatty acid intakes, 799-802
 sugar inadequacy, 809
- High-fiber diets, 297, 374, 378-379, 383, 788, 839
- High fructose corn syrup, 294, 295
- High glycemic index diets, 302
- Hippuric acid, 604
- Histidine (indispensable), 589, 591, 592, 593, 597, 604, 662, 663-665, 666, 668, 672-675, 678-682, 686, 687, 689, 709, 712, 720-723, 736, 1004-1005
- Homocysteine, 302, 726
- Homovanillic acid, 735
- Honolulu Heart Program, 562
- Human chorionic somatomammotropin, 189
- Human milk. *See also* Breastfeeding;
 Formulas, infant; Infants; Lactation
 amino acid content, 598, 607, 621, 657, 663, 664-665, 686, 687
 and behavioral development, 621
 bioavailability of nutrients, 431, 447, 621, 944
 carbohydrate content, 281-283, 292
 cholesterol, 546-549
 energy content, 171, 172-173, 199, 457, 461, 468, 474, 477
 energy cost of synthesis, 195-196
 energy output, 199
 fat content, 281, 431, 456, 458-459, 468
 fiber content, 385
 and immune function, 621
 monounsaturated fatty acids, 474, 477
 nonprotein nitrogen content, 620, 657, 658
 nutritional adequacy, 31, 447, 456, 662, 663
 polyunsaturated fatty acids, 447, 461, 462-463, 466, 467
 protein content, 620, 622-623, 657, 658, 686, 687
 saturated fatty acids, 474, 475-476
trans fatty acids, 479, 480
 volume of intake, 31, 45, 171, 172-173, 281, 456, 663
- Human studies. *See also* Balance studies
 advantages, 91, 98
 amino acids, 608-699, 702-703, 705-706, 712, 714-715, 720, 722-723, 724-725, 726, 727, 729, 730, 731-733, 735
 controlled, 40
 dose-response assessment, 98
 feeding trials, 40-41
 limitations of, 40-41, 94
- Hunger, 117, 313, 732, 795, 796
- Hydrogenated fat, 427-428, 436, 455, 456, 479, 495, 498-504, 836
- 5-Hydroxyindoleacetic acid, 732
- Hydroxylysine, 593
- 3-Hydroxy-3-methylglutaryl coenzyme A, 545
- Hydroxyproline, 592-593, 728-729
- Hyperactivity, 295
- Hyperammonemia, 699, 714, 718
- Hypercalciuria, 694, 841
- Hyperchloremic acidosis, 698
- Hypercholesteremia, 276, 352, 355, 356, 358, 359, 366, 367, 494, 495, 721, 811, 842
- Hyperglutamic acidemia, 718
- Hyperglycemia, 275, 353, 815
- Hyperinsulinemia, 130, 784-785, 802-808, 832
- Hyperkalemia, 699
- Hyperlipidemia, 130, 302, 304-308, 322, 323, 355, 362-368
- Hyperlipoproteinemia, 359
- Hyperphenylalaninemia, 728
- Hypertension, 57, 735
 BMI and, 124, 230-231
 fiber and, 60, 362-368, 369
 polyunsaturated fatty acids and, 59
 protective effects of nutrients, 59, 362-368
 risk factors, 130

Hyperthermia, 910, 926-927
 Hypertriacylglyceridemia or
 hypertriacylglycerolemia, 59, 297,
 323
 Hypoalbuminemic malnutrition, 608
 Hypoenergetic diet, 311
 Hypoglycemia, 295, 910
 Hyponatremia, 699
 Hypothermia, 927
 Hypothermogenicity, 696
 Hypoxia, 149

I

Ileostomy patients, 357
 Imino acids, 591, 592
 Immune function, 57, 396, 439, 487-492,
 697-698, 699, 839
 Immunosuppression, 492
 Indian Experiment of Infarct Survival, 828
 Indicator amino acid oxidation (IAAO)
 method, 617-619, 670-671, 676, 677,
 678
 Indicators of nutrient adequacy. *See also*
 specific indicators, nutrients, and life
 stages
 methodological considerations, 43
 risk reduction-based
 Infants, 0-12 months. *See also* Formulas,
 infant; Human milk; Life-stage
 groups
 ages 0 through 6 months, 31, 35, 44, 45,
 169, 199, 201, 281, 283, 385, 456-457,
 461, 468, 619-623, 662-665
 ages 7 through 12 months, 31-32, 35, 45-
 46, 169, 199, 283, 385, 457, 461, 468,
 624-630, 664-670, 672
 AIs, 4, 26, 30-32, 44-46, 280-283, 456-457,
 460-461, 466-469, 619-623, 662-665,
 944, 946
 amino acids, 30, 45, 594, 598, 607, 614,
 619, 621, 662-670, 672, 686, 687, 719,
 722-723, 724, 726
 birth weight, 456, 471, 650, 654, 719,
 731, 811, 839, 840, 910
 BMI, 1106-1114
 BMR, 164-165, 1106-1114
 body fatness, 142, 621
 brain development, 280, 288-289, 291,
 445, 448-451, 466, 468, 545, 548, 608-
 609

carbohydrate, 30, 32, 46, 280-283, 288-
 289, 291
 cholesterol, 545-549
 dietary intakes, 30, 46, 170, 171, 199,
 457, 624
 EARs, 46, 624-629, 664-670, 672
 EERs, 32, 45, 46, 164-171
 energy expenditure and deposition, 116,
 122-123, 164, 167
 extrapolation of data from adults to, 46,
 47
 extrapolation of data from younger to
 older infants, 31-32
 factorial modeling, 624, 628
 fat, 4, 30, 32, 46, 432, 437, 456-459, 769,
 816
 fiber, 385
 formula-fed, 26, 31, 45, 165, 166, 168,
 280-281, 283, 446-447, 448-451, 454,
 461, 463, 466, 468, 621
 glucose metabolism, 280, 281, 288-289
 growth, 30, 45, 142, 164, 166-168, 280-
 281, 436, 437, 445, 446-447, 448-451,
 457, 460, 465, 468, 472, 607, 609,
 611, 630, 669, 982
 hyperammonemic, 699
 language development, 447
 malnutrition, 165, 167, 608-609
 methodological considerations, 44-46
 milk consumption, 26
 monounsaturated fatty acids, 432
 newborn, 92, 142, 165, 166, 291, 433,
 594, 595, 598, 603
 nitrogen balance studies, 624-627
 of overweight mothers, 134
 on parenteral nutrition, 722-723
 phenylketonuria, 728
 physical activity, 166
 polyunsaturated fatty acids, 30, 46, 433,
 435, 438, 439, 440, 445-447, 448-451,
 454, 460-463, 472
 premature, 122-123, 165, 166, 167, 280,
 435, 445, 447, 456, 469, 594, 607,
 609, 719, 731, 840, 910
 protein, 30, 45, 46, 595, 602, 603, 608-
 609, 611, 619-630, 669, 686, 687
 RDAs, 31, 629-630, 672
 recommended food sources, 26, 31, 32,
 45, 46
 saturated fatty acid, 431
 sleepiness, 733

- special considerations, 45, 283, 457, 461, 463, 469, 621-623
- TEE, 166, 168, 169, 170, 1106-1114
- thermic effect of food, 165
- thermoregulation, 165-166
- trans* fatty acids, 456
- visual development, 448-451
- weight and height, reference, 35, 132-135, 1106-1114
- weight gain, 46, 621
- zinc, 722-723
- Inflammatory disorders, 824
- Institute of Medicine, 45, 46
- Insulin resistance, 2, 62, 63, 189, 275, 291, 303, 306-307, 308-312, 320, 784-785, 802-808, 921. *See also* Diabetes mellitus
- Insulin Resistance Atherosclerosis Study, 803
- Insulin response. *See also* Hyperinsulinemia
- age/aging and, 62
- amino acids, 696, 701, 705, 710
- and cancer, 320
- to carbohydrate intake, 268, 269, 273, 274, 275, 277, 303, 320, 437
- and diabetes, type 2, 63, 275, 303, 306-307, 308-312, 784-785
- epidemiological studies, 380-381
- to fat, 62, 303, 430, 437, 438, 484-485, 802-808
- fiber intake and, 60, 63, 297, 306-307, 339, 351, 353, 355-356, 360, 380-382, 388
- to glucose metabolism, 268, 273, 274
- glycemic index of foods and, 63, 269, 306-307, 308-312, 322
- hazard identification, 303, 306-307
- intervention studies, 381-382
- metabolic syndrome, 802
- obesity and, 62, 303, 784, 802, 803
- oral contraceptives and, 921
- parenteral nutrition, 438
- physical activity and, 60, 62, 63, 303, 803, 921
- pregnancy and, 189, 291
- to protein intake, 279, 602
- sensitivity of, 62, 63, 189, 291, 303, 306-307, 308-312, 322
- to undernutrition, 220
- Insulin-like growth factors, 320
- Interactions of dietary factors
- adverse, 85, 95
- amino acids, 721-723, 725, 726, 731
- and bioavailability, 93, 271, 281, 424
- and blood pressure
- fatty acids, 453-456
- methodological issues, 41-42, 53, 376-377
- Intermediate density lipoproteins, 545
- Intervention studies
- breast cancer, 378-379
- carbohydrate, 785, 786-787
- CHD, 365-368, 798-799, 817-818, 821, 828-831
- colon cancer, 374-375, 376-377
- confounding of dietary factors, 376-377
- design features, 43
- diabetes mellitus (type 2), 381-382, 785, 786-787, 806-807, 832-833
- of dietary patterns, 43
- fiber and disease prevention, 344, 351, 365-368, 374-377, 378-379, 381-382, 383-384
- glucose response, 381-382, 803-807
- high fat, low carbohydrate diets, 794-796, 798-799, 803-807
- hyperlipidemia prevention, 365-368
- hypertension prevention, 365-368
- insulin response to fat intake, 803-807
- low *n*-9 monounsaturated fatty acid diets, 817-818
- meta-analyses, 58, 777, 798
- methodological issues, 43, 376-377
- obesity, 311, 773-776, 794-796, 797
- polyunsaturated fatty acids, 821, 828, 830-831, 832-833
- satiety and weight maintenance, 383-384
- timing of, 376
- Intestinal absorption. *See also individual nutrients*
- active transport, 273
- aging and, 447, 450-452
- estrogen, 378
- facilitated diffusion, 273
- fiber intake and, 60, 348, 378, 383
- glucose, 382, 383
- monosaccharides, 272-273
- and sensitivity to nutrient toxicity, 92
- slowing, 323
- Intestinal metabolic dysfunction, 594
- Intestinal obstruction, 395, 398
- Inuits, 275

Inulin (dietary or functional fiber), 341,
345, 353-354, 390, 391, 394, 397, 838
Iowa Women's Health Study, 307, 363
Irritable bowel syndrome, 353-354, 358, 395
Iron, 391, 394, 398, 725, 771, 789, 790-793,
812, 813, 840, 981, 982, 1204-1211,
1214-1221, 1224-1225, 1228-1243
Isoleucine (indispensable), 589, 591, 593,
597, 662, 663-665, 666, 668, 669, 672-
675, 678, 679-682, 686, 687, 689, 704-
711, 736, 1006-1007
Isomaltose, 272

J

Joint FAO/WHO Expert Committee on
Food Additives, 90, 713

K

KANWU study, 485
Karaya gum, 367, 382, 838
Keratin, 592
Ketoacids and ketosis, 276, 277, 278-279,
280, 281, 284, 287, 289, 290-291, 430,
604, 605, 704
Kidney stones, 841-842
Krebs-Henseleit cycle, 604-605, 606

L

Lactase, 272, 592
Lactate, 276
Lactation. *See also* Breastfeeding; Human
milk
adaptation to, 34, 47, 197, 290, 291, 650
adolescents, 201, 293, 388-389, 465-466,
471-472, 659
AIs, 34, 388-389, 465-466, 471-472
amino acids, 681-682
BMR, 195-196
and body weight, 199-200, 201
carbohydrates and, 196
derivation of DRIs for, 34, 48
EARs, 34, 292-293, 656-659, 681
EERs, 107, 116-117, 195-202
and energy expenditure, 116, 198-199
energy mobilization, 34, 199-200
fiber, 388-389

milk energy output, 172-173, 199
physical activity, 197-198, 199, 1166-1167
polyunsaturated fatty acids, 465-466, 471-
472
protein, 840
RDAs, 293, 659, 682
stage of, 172-173
TEE, 116, 198-199, 201, 1166-1167
TEF, 196-197
total energy requirements, 200-201
ULs, 92
Lactose, 266, 267, 268, 272, 273, 281, 282-
283, 292, 813
Lactulose, 397
Lauric acid, 58, 425, 483
Laxation, fiber consumption and, 339, 350,
351, 352, 353-354, 355, 356, 357-358,
360-361, 370-371, 372, 385-386, 388
LDL cholesterol. *See also* Lipoprotein
metabolism
carbohydrate intake and, 781, 782-784,
797
and CHD risk, 57, 481-484, 542, 548-549,
573, 798-799, 815
children, 815
cholesterol intake and, 544-545, 548-562,
563, 568, 569, 573
fiber intake and, 59, 351, 352, 355, 356,
357, 358, 359, 361, 365-366, 367-368
glycemic index and, 302
hazard identification, 549, 560-562
low fat, high carbohydrate diets and,
777-781
monounsaturated fatty acids and, 58,
486, 817-818
polyunsaturated fatty acids and, 58-59,
821, 822-823, 828, 830-831
protein intake and, 60
saturated fatty acids and, 58, 422, 432,
481-484, 798-799
sugar intake and, 297-301, 302
trans fatty acids and, 58, 423, 494-503, 504
Legumes, 365, 366, 370, 382, 390
Leucine (indispensable), 589, 591, 593, 596,
597, 617, 618, 650, 660, 663-665, 666,
668, 671-682, 686, 687, 689, 704-711,
736, 1008-1009
Leukotrienes, 434, 454, 824, 838
Life-stage groups. *See also* Adolescents;
Adults; Children; Infants; Toddlers
alcohol, 1064-1065

- amino acids, 662-682, 992-1027
 carbohydrates, 6, 280-293, 988-991, 1032-1033, 1068-1069
 categories, 30-34
 cholesterol, 546-549, 1058-1059
 EERs by, 5, 164-223
 energy, 1028-1031, 1034-1035, 1040-1041, 1062-1067, 1072-1075
 fat (total) by, 9, 456-460, 1038-1041, 1070-1071
 fiber, 384-390, 1036-1037
 intakes by, 988-1065
 monounsaturated fatty acids, 1044-1045
 polyunsaturated fatty acids, 11, 460-466, 820, 1046-1057
 protein (total) by, 619-662, 1060-1063, 1074-1075
 saturated fatty acids, 1042-1043, 1072-1073
 and toxicological sensitivities, 97-98
 weights and heights, reference
 Lignin (dietary fiber), 344, 346, 350, 356
 Limit dextrins, 272
 Linoleic acid. *See also* α -Linoleic acid;
 Conjugated linoleic acid
 absorption, 431
 AIs, 5, 8, 10, 423, 460-461, 463-466, 770, 822, 825, 944
 AMDRs, 15, 770, 825-826
 and cancer, 825
 and CHD, 821
 deficiency, 4-5, 423, 426, 438, 464
 dietary intakes, 8, 478, 1044-1045
 food sources, 771
 function, 38, 423, 426-427
 in infant formula, 461, 463
 interaction with α -linoleic acid, 447, 453-455, 472, 825
 by life stage and gender group, 10, 460-466
 and lipid peroxidation, 824, 838
 metabolism, 433, 434, 440, 442, 453, 455-456, 476, 838
 protective effects of, 821
 supplementation, 442, 444
 trans fatty acids and, 455-456
 Lipids and lipid metabolism
 aging and, 922
 amino acids and, 724, 731
 carbohydrates and, 275, 277, 278-279, 297-303, 781, 782-784, 917-923
 cardiovascular disease, 302, 562-569
 and CHD, 57, 60, 356, 481-484, 562-569
 fatty acids and, 424-425, 430-431, 493
 fiber and, 297, 350, 351, 352, 354, 355, 356-357, 358-359, 360, 361, 365-366, 388
 glycemic index of diet and, 269, 270-271, 297, 302-303, 304-308
 and growth and development, 922-923
 peroxidation, 493, 504, 823-824, 838
 physical activity and, 430, 917-923
 sugars and, 297-302
 thermoregulation and, 166
 weight loss and, 204
 Lipolysis, 277
 Lipoprotein (a), 503
 Lipoprotein lipase activity, 61
 Lipoprotein metabolism, 61, 369, 429, 436, 438, 544-545, 548, 562, 563, 568-569, 573, 815. *See also* Cholesterol; HDL cholesterol; LDL cholesterol
 Liver
 alcohol dehydrogenase, 108-109
 disease, 705
 function, 92, 704, 705, 721
 Locust bean gum, 367, 382
 Longevity, composition of energy sources and, 39
 Low density lipoprotein (LDL), 431. *See also* LDL cholesterol
 oxidation, 504, 823-824
 Low fat, high carbohydrate diets
 added sugars, 788-789, 812-813
 adults, 772-792
 and cancer risk, 772
 CHD risk, 437-438, 772, 777-784
 children, 438, 810-814
 diabetes (type 2) risk, 437-438, 772, 784-785
 and diarrhea, 438
 epidemiological studies, 783, 785
 fat oxidation, 810
 fiber, 367, 788
 glucose intolerance risk, 784-785
 and growth, 810-811
 high monounsaturated fatty acid diet compared, 817
 and hunger, 795
 hyperinsulinemia, 784-785
 hypocaloric diets, 772

- intervention studies, 311, 773-776, 777, 785, 786-787
- isocaloric diets, 772, 773, 777
- and lipid levels, 777-781
- and micronutrient inadequacy or excess, 785, 788-789, 811-814
- and obesity, 769, 773-776, 777
- and physical activity, 773
- protein intake and, 843
- total sugars, 789, 792, 813-814
- and weight, 772, 773-777
- Low glycemic index diets, 304-307
- Low-protein diets, 648, 667, 697, 707, 709, 721, 731-732, 839-840
- Lowest-Observed-Adverse-Effect Level (LOAEL), 90, 98, 100-101, 224, 569, 975
- Lung cancer, 54-55, 319, 486, 568, 570-573, 808, 837, 844
- Luteinizing hormone, 715
- Lyon Diet Heart Study, 829
- Lysine (indispensable), 589, 591, 593, 597, 602, 608, 614, 616, 617, 618, 650, 661, 663-665, 666, 668, 669-670, 671-682, 685, 686, 687, 689, 692, 723-725, 736, 1010-1011
- ## M
- Macronutrients. *See also* Carbohydrate; Fat; Protein
- brain requirements, 771
- defined, 108
- imbalances and chronic diseases, 771
- integrated planning of intakes, 936-966
- Magnesium, 394, 789, 790-791, 813, 838, 1204-1211, 1214-1221, 1224-1225
- Malabsorption syndrome, 30
- Malnutrition, 167, 437, 595, 608-610, 704, 839. *See also* Starvation
- Malondialdehyde, 711
- Malonyl coenzyme A, 274
- Maltase, 272
- Maltodextrin, 360
- Maltose, 266, 272
- Mannitol, 266
- Mannose, 345
- Maple syrup urine disease, 704, 706
- Masai, 275
- Melanin, 608
- Men. *See also* Gender differences
- carbohydrate intakes compared to other nutrients, 1232-1237
- CHD, 363, 364
- cholesterol, 354
- diabetes type 2, 380, 381
- fiber, 363, 364, 380, 381
- lipoprotein profile, 61
- nutrient intakes with sugars, 1208-1213
- PAL, 893
- protein intakes, 695
- reference weights and heights, 125
- TEE, 147
- Menstrual cycle, 140, 141, 921, 928
- Mental health, 151, 276, 720, 913, 916
- Mental retardation, 728
- Menus, sample, 392-393
- Metabolic alkalosis, 699
- Metabolic disorders, 697, 700, 704, 705, 706, 710, 714, 727, 728, 735
- Metabolic equivalent, 975
- Metabolic syndrome, 802
- Metabolism. *See also* Basal metabolic rate; Glucose metabolism; Lipids and lipid metabolism; *individual nutrients*
- cellular uptake of nutrients, 273
- eiconasanoid, 55
- glycogen synthesis and utilization, 274
- insulin, 275
- intracellular utilization of sugars, 273-274
- physical activity and, 138
- splanchnic, 600, 717
- Methionine (indispensable), 589, 591, 593, 594, 597, 608, 614, 663-665, 666, 668, 672-675, 677, 678, 679-682, 685, 686, 687, 689, 711, 723, 725-726, 736, 1012-1013
- Methodological issues. *See also* Data and database issues; Indicators of nutrient adequacy
- AI derivation for infants, 44-46
- in balance studies, 40-41, 617, 676
- BMI, 121, 124-125
- brain blood flow methods, 280
- children, 25, 47-48
- confounding and bias, 41-42, 376-377, 451, 484, 643
- data sources, 39-44
- depletion-repletion studies, 40-41

- in dietary intake estimates, 42, 48, 49-50, 110, 116, 117-118, 307, 312, 313, 322, 563, 624, 643, 936-937
- direct amino acid method, 616-617, 618
- DLW method, 120-121, 152, 198
- EARs for children and adults, 25, 46-47
- epidemiological evidence, 40, 41-42, 322, 569
- experimental studies, 40
- extrapolation from animal studies, 40, 87, 95, 97, 98, 100, 101, 492, 562, 703, 705, 1245-1246
- extrapolation from other age groups, 25, 26-27, 31-32, 34, 44, 46, 47, 101, 283
- extrapolation from short periods to 24 hours, 616
- factorial approach, 25, 116, 118, 611, 981
- generalizability of studies, 41, 42, 100, 118
- glycemic index calculation, 307
- growth measurement, 142
- human feeding studies, 40-41
- indicator amino acid oxidation method, 618, 619
- interactions of dietary factors, 41-42, 53, 376-377
- intervention studies, 42-43, 376-377, 725
- Monte Carlo approach, 981-982
- multicollinearity, 42
- nitrogen balance method, 611-612, 635, 643, 644, 688
- in nutrient intake estimates, 41-42, 48-49, 941-945
- observational studies, 40, 41-42
- plasma amino acid response method, 615
- pregnant and lactating women
- randomized clinical trials, 40, 42-43, 376-377
- research needs, 969-970
- in risk assessment, 91-94, 100
- single treatment vs. multitreatment
 - parallel designs, 492
- supplementation trials, 43
- weighing the evidence, 3, 43-44, 94
- weight maintenance in overweight and obese adults, 202-204
- Methylcellulose (dietary fiber), 341
- Mevalonic acid, 545
- Mohawk Indians, 146
- MONICA Study, 316-317, 318-319, 790-793
- Monosaccharides, 59, 265, 266, 272, 276, 281, 297, 342
- Monosodium glutamate, 695, 712-713, 715-717
- Monounsaturated fatty acids (cis isomer).
 - See also individual fatty acids*
 - absorption, 432
 - adverse effects of overconsumption, 485-486
 - AMDR, 820
 - and cancer risk, 55, 486, 819
 - and cardiovascular disease, 485-486
 - and CHD risk, 58-59, 817-818
 - and diabetes, 819
 - dietary intakes, 474, 1044-1045
 - energy contribution, 474, 478
 - epidemiological studies, 817
 - evidence considered for estimating requirements, 441, 460
 - excretion, 433
 - food sources, 426, 474, 478, 816, 819-820
 - function, 4, 426, 432, 460
 - and glucose metabolism, 819
 - hazard identification, 485-486
 - high *n*-9 fatty acid diets, 820
 - insulin sensitivity, 806
 - intervention studies, 817-818
 - by life stage and gender groups, 1044-1045
 - and lipid profile, 58, 486, 817-818
 - low *n*-9 fatty acid diets, 817-820
 - metabolism, 4, 423, 432-433
 - and micronutrient inadequacy, 819-820
 - n*-9, 460
 - protective effects, 816-817, 819
 - research recommendations, 505
- Montreal Diet Dispensary, 654
- Mortality
 - BMI and, 484
 - saturated fatty acids and, 484
- MSG Symptom Complex, 714, 715-717
- Mucins, 592, 601, 683
- Multiple Risk Factor Intervention Trial, 827, 914-915
- Myosin, 593, 595
- Myristic acid, 58, 425, 483
- Myristoleic acid, 426

N

- N-Methyl-D-aspartate, 711
- National Cholesterol Education Program, 798
- National Health and Nutrition Examination Survey III, 36, 46
- adjustments to data, 49-50
 - at-risk-for-overweight category, 130
 - body composition data, 124, 125, 130, 982, 1078-1103
 - dietary intake data, 283, 295, 473, 474, 624, 701, 704, 711, 712, 720, 721, 723, 725, 727, 729, 730, 731, 734, 789, 792, 812, 988-1027
 - Epidemiological Follow-up Study, 827
 - lipid profiles, 302
 - survey design, 49
 - underreporting of energy intakes, 49
- National Institutes of Health, 121
- National Nutrition Monitoring System, 936
- National Nutritious Food Basket, 481
- National Research Council, 87
- Nationwide Food Consumption Survey, 314-315, 318-319, 474, 790-793
- Navajo Indians, 173
- Nervonic acid, 426
- Netherlands Cohort Study, 378
- Neural development, 444-447
- Neural tube defects, 726
- Neurological effects. *See also* Brain
- amino acids, 696, 699, 701-702, 703, 704-705, 706, 711, 714, 715, 717, 718, 719, 727, 728, 733
- Neurotransmitters, 704-705, 707, 709, 710, 711, 714, 731, 732, 734
- Niacin, 731, 790-791, 813-814, 1228-1243
- Nicotinamide adenine dinucleotide, 453
- Nicotinic acid, 608, 792-793
- Nitric oxide, 608
- Nitrogen. *See also* Protein
- amino acid utilization through
 - nonprotein pathways, 607-608, 684
 - balance, 275, 279, 287, 594, 611, 694, 718
 - carbohydrate-free diets and, 275
 - content in dietary protein, 590
 - factorial method, 610-611, 624, 628, 629
 - host-colon nitrogen cycle, 600
 - individual variation, 612-613, 634, 635, 649
 - losses, 598, 600-601, 610-611, 612, 625, 634, 635, 644, 646, 650, 667, 668, 671, 682-683
 - maintenance requirement, 667-669
 - median requirement, 635, 637-638
 - metabolism, 278, 598, 603-605, 718, 720
 - nonprotein, 607-608, 620
 - and potassium balance, 650-653
 - protein conversion factor, 684-685
 - protein/nitrogen ratio, 684-685
 - quality as protein source, 611, 684-685
 - sources, 594
- Nitrogen balance studies
- adolescents, 624-627, 632, 664-666
 - adults, 275, 287, 618, 633-643, 661
 - amino acids, 612, 613-614, 618, 662, 664-666, 670-671, 676, 677, 678, 688
 - animals, 671
 - children, 624-627, 664-666
 - data analysis, 639, 677
 - energy intake estimates and, 647, 648
 - factor analysis, 639-643
 - infants, 624-627
 - limitations, 611-612, 618, 635, 643, 644, 688
 - meta analysis, 643, 644, 646, 648, 691
 - older adults, 646-648
 - pregnant women, 650-653, 654-655
 - protein, 611-613, 633-635, 639, 642-643, 650-653, 654-655, 684, 691, 693, 1250-1253
 - statistical analysis of data, 612-613, 635, 638, 639, 642-643, 666
 - younger adults, 633-635, 639, 642-643
- No-Observed-Adverse-Effect Level (NOAEL), 90, 98, 100, 101, 975
- Non-Hodgkin's lymphoma, 844
- Norepinephrine, 277, 735, 916
- Normative Aging Study, 484
- Normative requirement, 24
- Nuclear peroxisome proliferator activating receptors, 425
- Nurses' Health Study, 306-307, 363, 368, 376, 377, 387, 563, 827-828, 842
- Nutrient intakes. *See also* Dietary intakes
- added sugar intakes and, 788-789, 790-793, 1203-1225
 - adjusting for day-to-day variation, 29, 49-50
 - assessment of, 42, 48-49, 937-945
 - bioavailability and, 29-30

- biochemical assessment, 944
 - calculation of, 941-945
 - carbohydrate compared to other nutrients, 1226-1243
 - carbohydrate intake and micronutrients, 812, 816, 1226-1243
 - chronic intakes above the UL, 104, 105
 - high fat, low carbohydrate diets and, 808-809, 816
 - low fat, high carbohydrate diets and, 785, 788-789, 811-814
 - methodological considerations, 41, 42, 46, 48-49, 941-945
 - probability approach, 942-943, 944
 - special considerations, 30
 - Nutrient requirements, energy requirements compared, 110-111
 - Nutrition Canada Survey, 983
 - Nutrition labels, 267, 340, 341
- O**
- Oat products, 60, 355-356, 365, 366, 368, 378, 382, 394
 - Obesity and overweight
 - abdominal, 62, 64, 379, 802
 - as adaptation, 150
 - adolescents, 313, 815, 1172-1173, 1178-1183, 1202
 - adults, 153, 310-313, 814, 1184-1199, 1201
 - amino acids and, 701, 704, 732
 - appetite sensations and, 795
 - BEE, 217
 - BMI, 126, 204, 216, 310, 313
 - body fat content, 126
 - carbohydrate intake and, 65, 275, 307, 310-319, 769
 - and CHD risk, 130, 815
 - children, 65, 130, 134, 140, 153, 216-219, 307, 310, 312-313, 459, 811, 814, 923, 1168-1179, 1200, 1202
 - children of obese parents, 133
 - and diabetes type 2, 802, 803
 - DLW database, 153, 156-157, 202
 - energy density of foods and, 794-796
 - and energy expenditure, 111, 122-123, 133-135, 138, 140, 209, 212, 216-219
 - energy intakes, 54, 65, 111, 307, 310, 312, 313, 322, 794
 - and energy requirements, 110, 132-133, 135, 138, 202-213, 216-219
 - epidemiological studies, 792-794, 796-797
 - fat intake and, 64, 459, 460, 769, 772, 773-776, 792-797, 802, 803, 814
 - fiber intake and, 65, 352, 370, 382-384
 - genetic factors, 146, 452, 784
 - glucose metabolism, 204, 802
 - glycemic index and, 313, 322
 - health risks, 64, 130, 204, 224
 - high fat, low carbohydrate diets and, 769, 792-797
 - insulin resistance, 62, 303, 784, 802, 803
 - intervention studies, 311, 773-776, 794-796, 797
 - lipid metabolism, 204
 - management, 204
 - mechanisms for, 794-796
 - palatability of foods and, 795
 - physical activity and, 56, 65, 133, 140, 181, 209, 212, 1168-1182, 1184-1199
 - polyunsaturated fatty acids and, 832
 - pregnancy, 191
 - prevalence, 773
 - protein intake and, 694, 843
 - and reference weights and heights, 982
 - resting metabolic rate, 133, 135, 137
 - risk factors, 64, 65
 - saturated fatty acids and, 484
 - sugar intake, 307, 310-313, 314-319, 323
 - susceptible populations, 134
 - TEE, 133, 153, 156-157, 202-204, 209-213, 1168-1182, 1184-1199, 1201-1202
 - TEF, 133-134, 143
 - and underreporting of energy intakes, 42, 64, 65, 313, 938
 - weight loss, 204, 209, 212, 219, 311, 313, 370
 - weight maintenance, 202-209, 216-219, 382-383, 384, 732
 - weight regain following weight loss, 135
 - Observational studies. *See also*
 - Epidemiological studies
 - methodological issues, 40, 41-42, 94
 - Oleic acid, 426, 431, 432-433, 436, 439, 442, 455, 483, 486, 495, 819
 - Oligofructose (dietary or functional fiber), 353-354, 390, 391, 396-397
 - Oligosaccharides (dietary or functional fiber), 265, 272, 341, 342, 344, 592
 - Olive oil, 55
 - Ophthalmologic effects, 711, 714, 720, 722, 729, 734, 735, 736

Oral and pharynx cancer, 844
 Oral contraceptives, 921
 Ornithine, 697
 Osteoarthritis, 236-237
 Osteoporosis, 841, 928
 Ovarian cancer, 56, 379
 Oxaloacetate, 604, 701
 Oxyterols, 545-546

P

Palmitic acid, 58, 425, 431, 432, 483
 Palmitoleic acid, 426, 486
 Pampas indigenous people, 275
 Pancreatic
 cancer, 57
 disease, 395
 lipase, 429, 431
 Parenteral nutrition, 438, 442, 444, 460,
 469, 699, 705, 714, 718, 719, 722-723
 Pathobiological Determinants of
 Atherosclerosis in Youth Study, 815
 Pectins (dietary and/or functional fiber),
 63, 346, 348, 352, 356-357, 365, 366,
 369, 371, 382, 388, 390, 391, 394,
 397-398
 Phenylalanine (indispensable), 589, 591,
 593, 596, 597, 616, 617, 618, 663-665,
 666, 668, 671-682, 686, 687, 689, 695,
 703, 709, 726, 727-728, 734, 736,
 1014-1015
 Phenylketonuria, 619
 Phosphatidylethanolamine, 444
 Phosphatidylserine, 435, 444
 Phospholipids, 425, 429, 433, 434
 Phosphorus, 789, 790-791, 812, 813
 Physical activity. *See also individual life-stage
 groups*
 adaptations in, 197, 201, 220, 922
 adverse effects of excessive activity, 180,
 926-929
 age and, 143-144
 amino acids and, 918
 and appetite, 884
 and BMI, 880, 884
 and body fat, 57, 61, 139, 180, 181
 Canadian recommendations, 883, 913
 and cancer, 56-57
 and cardiovascular health, 60-61, 882,
 887-888, 913, 927
 and CHD risk, 60, 886-887, 924
 and chronic disease prevention, 912-917
 climate and, 147, 148
 cycling, 184, 190, 895
 daily living activities, 886, 895, 898-899,
 902-903
 data limitations, 180
 defined, 179, 881
 and diabetes mellitus type 2, 63-64
 DLW studies, 880, 881, 911
 duration, 138, 139, 183, 884, 918, 920-
 921
 elderly individuals, 138, 922
 energy expenditure of, 115-116, 117,
 133, 138-140, 141, 143-144, 145-146,
 147, 183, 190, 209, 212, 884-913
 and energy requirements, 38, 138-140,
 157-161, 166, 171, 174, 175, 176-181,
 182, 183-184, 190, 197-198
 epidemiological studies, 912-917
 and fat balance, 57, 60, 452
 and fatigue, 920, 921
 fidgeting, 118-119, 139-140, 902
 gender differences, 140-141, 182
 genetic influences, 145
 and glucose metabolism, 60
 glycemic index and, 318-319
 and growth and development, 922-923
 health benefits, 180-181, 912-917
 history of recommendations, 882-883, 913
 and immune function, 57
 insulin response, 60, 62, 63, 303, 803,
 921
 intensity, 139, 140, 148, 183, 190, 884,
 885-886, 904-905, 910, 918-920, 921,
 922
 leisure activities, 885, 896-897, 900-901,
 912-913
 and lipid balance, 57, 60, 61, 452, 913,
 917-923
 and mental health, 151, 881, 913, 916
 metabolic equivalents, 884-887, 888, 896-
 899, 903, 906, 917
 and mortality rates, 912-917
 obese and overweight individuals, 56, 65,
 133, 140, 181, 209, 212, 1168-1182,
 1184-1199
 and obesity, 56, 65, 784, 923
 and PAL, 884-912
 prevention of adverse effects, 928-929
 protective effects of, 56, 62
 protein requirements, 660-661, 918, 920

- recommended, 4, 56, 880, 882-883, 910, 911-912, 913, 926, 928-929
- reported, 184
- research recommendations, 225, 829
- residual effects of, 112, 139
- and skeletal health, 66, 180, 928
- sleeping, 118
- special considerations, 660-661
- spontaneous nonexercise activity, 139-140, 146
- TEF and, 884, 886, 895
- trends in, 881-882
- walking, 115, 116, 140, 158, 161, 183-184, 190, 881, 889-894, 895, 903, 906-909, 912, 913, 927
- and weight control, 209, 452, 888, 908
- Physical activity level (PAL)
 - active lifestyle, 158, 162-163, 895-899, 900-903
 - age/aging and, 143
 - BEE and, 887, 888, 895
 - BMI and, 220, 223, 814, 911
 - and BMR, 115, 902
 - body weight and, 116, 184, 889, 891-895
 - calculation, 887-889
 - categories, 157-161, 162-163, 164, 183
 - and chronic disease risk reduction, 914-917
 - defined, 116, 174, 887
 - DLW studies, 895
 - evaluation of, 118, 180, 895-909
 - exercise program, 209
 - gender differences, 903, 904-905
 - and glycemic index of foods, 318
 - impact of activities on, 884-912
 - intensity of physical activity and, 138, 184, 887-889, 904-905
 - low-active lifestyle, 158, 162-163, 183, 895-899
 - measurement, 174
 - reference activity, 889
 - RMR and, 917
 - sedentary, 115, 118-119, 140, 183, 200, 895-899
 - TEE and, 157-161, 162-163, 164, 884, 887, 906-909
 - very active lifestyle, 115, 138, 158-159, 162-163, 895-899
- Physical exercise
 - adaptations in program, 928
 - age and, 922, 924
 - amino acid supplements and, 702, 705-706
 - athletes, 115, 138, 139, 180, 918, 924, 925
 - and body composition, 922, 923, 924
 - carbohydrate balance and, 64, 318-319, 452, 917-923, 924-925
 - and carbohydrate/electrolyte beverages, 924-925
 - and cardiovascular events, 927
 - defined, 881
 - and dehydration, 926-927
 - duration, 918, 920-921
 - endurance (aerobic), 61, 138, 140, 143, 318, 452, 660, 882, 916, 917, 918, 923, 924
 - energy expenditure for, 884, 924
 - excess post-exercise oxygen consumption, 112, 139
 - female athlete triad, 928
 - gender differences, 921, 928
 - and growth and development, 180, 922-923
 - and hyperthermia, 910, 926-927
 - and hypothermia, 927
 - intensity, 918-920, 921, 922, 925
 - and lipid oxidation, 917-923
 - overuse injuries, 926
 - physical education in schools, 923, 924
 - pregnancy and, 907, 908-911
 - recovery from illness and, 922
 - resistance exercise, 223, 661, 925, 928
 - running, 115, 138, 184, 223, 892, 893, 894, 926
 - treadmill, 184, 913
 - and weight, 61, 115-116, 213-215, 452, 773
- Physical fitness
 - defined, 179-180, 881
 - endurance (aerobic) training and, 923
 - intensity of exercise and, 140
 - objectives, 883
 - pregnancy and, 907-908
 - resistance exercise and, 925, 928
 - and spontaneous physical activity, 139
 - supplementation of water and nutrients, 925-926
- Physicians' Health Study, 827, 828
- Phytochemicals, 369, 379, 391, 394, 395, 788
- Pima Indians, 134, 146, 804-807
- Pituitary adenomas, 396
- Planet Health, 318-319

- Planning nutrient intakes
 AI and, 946, 948
 AMDR and, 946, 948-949
 carbohydrate, 956-957, 964
 EAR and, 947-948
 energy, 949-956, 963, 964
 fat, 959
 fiber, 957-958, 964
 of groups, 947-949, 952-954
 of individuals, 946, 949-952
 integrated example, 963-964, 965
 polyunsaturated fatty acids, 959-960, 964
 protein and amino acids, 946, 961, 964
 RDA and, 946
 saturated fatty acids, *trans* fatty acids,
 and cholesterol, 960
 UL and, 946, 947-948
- Plant sterols, 544
- Plasma amino acid response method, 614-615, 670-671
- Poland and United States Collaborative Study on Cardiovascular Epidemiology, 484
- Polydextrose (dietary or functional fiber)
 adverse effects, 398
 characteristics, 341, 346-347
 laxation, 357
 and lipid concentrations, 357
 uses, 36
- Polyp Prevention Trial, 374
- Polysaccharides, 265, 341, 342, 343, 344, 350, 377
- Polyunsaturated fatty acids, *n*-3. *See also* α -Linoleic acid; *other individual fatty acids*
 absorption, 434
 adverse effects of, 63, 487-494
 AMDRs, 834-835
 animal studies, 444-445, 492
 and bleeding time, 492-493
 and blood pressure, 829
 and body fat, 832
 and cancer, 54, 55, 833-834
 and carbohydrate utilization, 832
 and cardiovascular disease, 59, 455
 and CHD, 59, 62-63, 455, 492, 826-827, 828-829
 deficiency, 439-440, 443-447, 454-455, 469, 834
 and diabetes, 494, 832-833
 dietary intakes, 478, 959-960, 944, 1048-1057
 epidemiological studies, 826-828, 832
 evidence considered for estimating requirements, 443-447
 excretion, 435
 food sources, 478, 771
 function, 8, 443, 444-445, 446, 466, 468, 469
 and glucose metabolism, 833
 and growth, 444-447, 468, 469, 471
 hazard identification, 487-493
 high-intake diets, 834
 and immune function, 443, 487-492, 834
 and insulin sensitivity, 832-833
 interaction of *n*-6 and, 453-454
 intervention studies (nonclinical), 828, 830-831, 832-833
 and learning behavior, 445, 446, 447
 by life stage and gender group, 11, 466-473, 1048-1049
 and lipid profile, 826, 828, 830-831
 low intake diets, 826-834
 metabolism, 434-435, 439, 445-447, 453-456, 466
n-6:*n*-3 ratio, 8, 434, 439, 446-447, 454-455, 472, 834
 and neural development and function, 443, 444-445, 446, 466, 468, 469
 and obesity, 832
 oxidative damage, 493, 832
 parenteral nutrition and, 443, 454-455, 469
 protective effects of, 55, 826-834
 randomized controlled clinical trials, 446, 828-829
 research recommendations, 509, 514
 special considerations, 469, 471-472, 494
 and stroke risk, 59, 492-493, 827-828, 829, 834
 supplements, 455, 471-472, 487-491, 492-493, 494, 828, 829, 832, 833
 and total fat, 58
trans fatty acid impact, 455-456
 vegetarian diets, 466
 and vision, 443, 444, 445, 446
- Polyunsaturated fatty acids, *n*-6. *See also* Linoleic acid; *other specific fatty acids*
 absorption, 433
 adverse effects of overconsumption, 486, 825
 adverse effects of underconsumption, 821-822

- AIs, 461, 944-945
 AMDRs, 486, 825-826
 and cancer risk, 54, 824-825
 and CHD, 59, 434, 798-799, 820-821
 deficiency, 8, 438-439, 442, 454-455, 460, 463, 464, 785
 and diabetes risk, 821
 dietary intakes, 442, 478, 944, 959-960
 energy contribution, 478, 821
 epidemiological studies, 820-821
 evidence considered for estimating requirements, 442-443
 excretion, 434
 food sources, 476, 822
 function, 426-427
 and glucose metabolism, 821
 high-intake diets, 823-825
 and immune function, 439
 and inflammatory disorders, 824
 interaction of *n*-3 and, 453-454
 intervention studies, 821
 by life stage and gender group, 10, 460-466
 and lipid peroxidation, 823-824
 and lipid profile, 59, 798-799, 820-821, 822-824
 low fat diets and, 785
 low intake diets, 820-823
 metabolism, 8, 433-434, 442, 443, 453-456, 476
n-6:*n*-3 ratio, 8, 434, 439, 442, 446-447, 454-455, 472, 834
 parenteral nutrition and, 438, 442, 444, 454-455, 460, 464
 primary, 426
 requirement, 38
 research recommendations, 508-509
 special considerations, 461, 463
trans fatty acid impact, 455-456
- Potassium, 650-653, 725, 838
 Prealbumin, 609, 610
 Pregnancy. *See also* Lactation
 adaptation to, 34, 47, 197, 290, 291, 650
 adolescents, 48, 193, 201-202, 292, 389, 465, 471-472, 650-652, 654, 655
 AIs, 34, 47, 388, 465, 471-472
 amino acids, 680-681, 709, 724, 726, 732, 735
 animal studies, 709, 726
 BMR, 185, 188-191, 291
 body composition, 188, 191-192
 carbohydrates, 188
 cervical ripening, 472
 CHD risk, 389
 derivation of DRIs for, 34, 47-48
 DLW studies, 193, 196-197, 290
 EARs, 34, 47, 290-292, 650-655, 680
 EERs, 107, 116-117, 185, 188-194, 437
 energy metabolism, 47, 185, 188-189, 193, 194-195, 197, 290
 fat (dietary), 290, 437
 fiber, 353, 388
 food supplementation trials, 654
 glucose metabolism, 189-190, 290-291
 growth of maternal and fetal tissues, 92, 190-192, 194-195
 insulin resistance, 189, 291
 multiparous, 656
 nitrogen balance studies, 650-653, 654-655
 obesity and overweight, 191
 obligatory fetal transfer, 47
 physical activity, 190, 197, 907-911, 1164-1165
 polyunsaturated fatty acids, 465, 471-472
 potassium balance, 650-653
 protein, 839
 RDA, 292, 656, 680-681
 special considerations, 656
 supplements, 654, 656, 726
 TEE, 116, 193, 197, 290, 1164-1165
 thermic effect of food, 190
 ULs, 92
 weight, 47-48, 188, 190, 191, 192, 196, 650, 652, 653, 655, 709, 726, 732, 908, 910
- Prolactin, 189, 715
 Proline (dispensable), 592, 593, 607, 697, 712, 717, 728-729, 736, 1016-1017
 Prospective studies, breast cancer and dietary fiber, 378
 Prostaglandins, 434, 838
 Prostate cancer, 54, 55, 56, 57, 321, 379, 486, 568, 578-579, 808, 819, 825, 833-834, 837, 844
 Protease, 602
 Protective effects
 α -linoleic acid, 427, 770
 amino acids, 726
 cancer prevention, 54, 55, 819, 833-834
 CLA, 428, 836-838
 diabetes type 2, 380-381

- fiber, 55-56, 59, 63, 322, 339, 348, 363, 367-368, 369, 372, 374, 375, 376-380
- Protein.** *See also* Amino acids; Nitrogen absorption, 114, 599-600, 609 adaptations to metabolism of, 47, 293, 596, 605, 611, 650, 657, 694 adverse effects of, 692-694 age/aging and, 595, 602, 640-641, 642 AIs, 619-621 allergies, 692 AMDR, 15, 769, 844 amino acid content, 279, 621, 666, 682, 685-686 and amino acid homeostasis, 595-598 assessment of nutritional status, 609-610 and birth weight, 840 and blood pressure, 60, 843 and BMR, 598 body composition and, 626-629, 644, 843 body reserve, 595-596, 602, 609 and cancer, 54, 843-844 catabolism, 278, 284 and CHD, 60 chemistry, 590-592 chronic disease risk, 694 climate and, 640-641, 642 clinical effects of inadequate intake, 608-609 complete, 691 and coronary artery disease, 694, 842-843 deficiency, 601-602, 608-610, 620, 662, 840 degradation, 602 deposition rates, 626-629, 665, 666, 669, 837 dietary intakes, 589, 596, 602-603, 624, 662, 692, 1060-1063, 1074-1075 digestion and digestibility, 9, 589, 592, 599-600, 621, 662, 682-684, 688-690 dose-response assessment, 694 EARs, 12-13, 624-629, 631, 637, 643-644, 646-649, 650-654 efficiency of utilization, 666 energy contribution, 109, 589, 605, 647, 648, 771, 1062-1063, 1074-1075 factorial method, 624, 628, 629, 633, 657, 658 FAO/WHO recommendations, 648 fat intake and, 60, 271, 693 food sources, 48, 280-281, 620, 622-623, 640-641, 643, 691, 771 food supplementation trials, 654 function, 9, 38, 589, 590 gastrointestinal effects, 694 gender difference, 640-641, 643, 644 and gluconeogenesis, 278, 284, 287-288, 293 and glycemic index of foods, 269 and growth, 280-281, 608-609, 654, 683, 811, 839-840 hazard identification, 692-694 high-protein diets, 692-694, 712, 841-844 and immune function, 609, 621, 839 incomplete, 691 insulin response, 279 intake assessment, 695, 960-961 intestinal losses, 600-601 and kidney stones, 694, 841-842 by life stage and gender group, 12-13, 603, 619-662, 1060-1063, 1074-1075 and lipid profile, 60, 840, 843 low-protein diets, 648, 667, 697, 707, 709, 721, 731-732, 839-840 maintenance (homeostasis), 595-597, 598-599, 601-602, 625-627, 630, 632, 657, 660, 668, 683, 684 metabolism, 597-598, 609, 650, 657, 724 methods used to estimate requirements, 635, 637-639 micronutrient availability, 840, 841 nitrogen balance, 9, 279, 287, 611-613, 624-625, 632, 633-644, 650, 654-655, 684, 691, 693, 1250-1253 nitrogen/protein ratio, 684-685 and obesity, 694, 843 and osteoporosis, 694, 841 oxidation, 109 physical activity and, 660-661 planning diets, 946, 961, 964 quality, 14, 60, 589, 608, 611, 621, 643, 661-662, 682-691, 697, 721, 811, 840 RDAs, 9, 12-13, 25, 47, 278, 589, 612-613, 629-630, 631-633, 644-645, 649, 656, 659, 844, 946 and renal function, 609, 694, 842 research recommendations, 737 risk characterization, 695 selection of indicators for estimating requirements, 610-613 special considerations, 621, 656, 660-662 sugar intakes and, 790-791 supplementation, 654, 656, 692, 694, 840

- synthesis, 114, 601-602, 603, 708-709
 thermic effect of, 110, 114
 total, 619-662
 turnover, 598, 601, 602-603, 611, 650, 655, 705
 ULs, 692-695
 urea production, 594, 601, 603, 604-605, 611, 620, 650, 657, 671, 684, 693-694
 vegetarians, 661-662, 840
 and weight, 644, 647, 650, 652, 653, 654, 655
- Protein digestibility corrected amino acid score (PDCAAS), 688-690
- Protein–energy malnutrition, 608-610, 704, 839, 840
- Protein-free diet, 278, 635, 648, 667, 683
- Psyllium (functional fiber), 347, 348, 356, 357-360, 365, 366, 371, 374-375, 388, 398-399, 693-694
- Puberty/pubertal development
 age at onset, 33, 983
 developmental changes, 177
 growth spurt, 142
 racial/ethnic differences, 33
- Purine nucleotide cycle, 604, 605
- Pyrimidine nucleotides, 620
- Pyruvate, 604, 605
- R**
- Race/ethnicity. *See also* African Americans;
 Caucasians
 and BMR, 146
 and energy expenditure, 145-146
 and pubertal development
 and reporting of dietary intakes, 117
- Raffinose, 265, 342
- Randomized clinical trials, 42-43, 828-829
- Recommended Dietary Allowance (RDA)
 AIs compared, 6, 26-27
 coefficient of variation, 24-25, 47, 285, 289, 292, 293, 630, 632-633, 645, 656, 670, 679, 682
 criteria used to derive, 6
 defined, 3, 22, 23, 24, 285, 289-290, 292, 293, 629
 derivation, 285, 629-630, 633, 644-645, 649, 656, 679, 682
 EAR and, 23, 24
 method used to set, 24-25, 34, 47, 981-982
 not established, 107
 replacement with DRIs, 1, 936-937
 uses, 24, 25, 26, 936, 938-939, 944, 946
- Recommended Nutrient Intakes (RNIs), 31, 936-937
- Reference weights and heights
 and BMI, 35, 36, 124, 125, 126, 127-130
 derivation of earlier values, 982-984
 and energy requirements, 183
 new, 35, 36, 982
 use of, 34, 47, 659
- Renal cancer, 844
- Renal failure, 842
- Renal function, 92
- Reproductive effects, 701, 712, 713, 715
- Requirement, defined, 21-22, 39
- Research recommendations. *See also individual nutrients*
 adverse effects, 970-971
 amino acids, 737-738
 approach to setting, 968
 body composition and size, 225, 240
 carbohydrates, 323-324
 cholesterol, 574-575, 578
 chronic disease relationships to intakes, 970
 data and database issues, 969-971
 energy, 225, 240, 323-324
 fat (total), 324, 505, 514
 fiber, 399-400
 major information gaps and, 18, 44, 969-971
 methodology, 969-970
 monounsaturated fatty acids, 505
 physical activity, 225, 829
 polyunsaturated fatty acids, 508-509, 514
 priorities, 18, 971
 protein, 737
 requirements, 969
 saturated fatty acids, 505
 trans fatty acids, 514
- Resistant dextrins (dietary or functional fiber), 341, 347, 360
- Resistant starch (dietary or functional fiber), 268, 342, 344, 347, 348, 360-361, 366, 371, 376-377, 378, 382, 384, 390, 399
- Respiratory quotient (RQ), 109, 119-120, 189, 196, 279, 291, 832
- Resting energy expenditure (REE), 112, 114, 128, 133, 141, 212

- Resting metabolic rate (RMR)
 aging and, 143
 body composition and size and, 131,
 135, 138, 144
 energy expenditure, 112, 131, 132, 141,
 148, 165
 FFM and, 113, 139
 gender differences, 141
 lactation and, 195
 menstrual cycle and, 141
 weight and, 113, 133, 135
- Retinol, 792-793
- Retinol binding protein, 609, 610
- Rheumatoid arthritis, 487, 722, 824
- Riboflavin, 790-791, 835, 840, 1228-1243
- Risk assessment models. *See also* UL
 modeling
 application to nutrients, 27, 91-94
 basic concepts, 86-87
 bioavailability considerations, 93-94, 98
 defined, 86, 976
 environmental chemicals vs. nutrients, 91
 EPA guidelines, 1246
 and food safety, 86-90, 104
 limitations, 100
 nutrient–nutrient interactions, 93
 process, 87-89, 97-98
 sensitivity of individuals, 89, 92-93, 97-98,
 100, 101
 thresholds, 89-90
 uncertainties, 86, 87, 91-92, 100, 1244-
 1249
- Risk characterization, 86, 89, 90, 976
- Risk management, 87, 89, 104, 976
- S**
- Satiety, 65, 313, 348, 382-384, 388, 794, 795,
 796, 843
- Saturated fatty acids. *See also individual fatty
 acids*
 absorption, 431-432
 adverse effects of overconsumption, 481-
 485
 and BMI, 484
 and cancer, 484
 and CHD risk, 422, 481-484, 797, 798,
 799
 and diabetes (type 2) risk, 484-485
 dietary intake, 474, 960, 1042-1043,
 1072-1073, 1076-1077, 1226-1227
 energy contribution, 474, 835, 1072-
 1073, 1226-1227
 evidence considered for estimating
 requirements, 441, 460
 excretion, 432
 food sources, 424, 425, 474, 475-476,
 771, 835, 836
 function, 4, 422, 425, 432, 460, 484-485
 and glucose tolerance, 484, 485
 hazard identification, 481-485
 high-intake diets, 836
 and insulin sensitivity, 62, 484-485, 806
 by life stage and gender group, 1042-
 1043, 1072-1073
 and lipid profile, 422, 432, 481-484, 560,
 561, 809, 835
 low intake diets, 835
 metabolism, 4, 432
 and micronutrient intakes, 835
 and mortality incidence, 484
 in nonvegetarian diets, 1076
 and obesity, 484
 properties, 424
 reducing intakes, 836
 research recommendations, 505
 and total fat, 58, 424
 in vegetarian diets, 835, 1076
- Schizophrenia, 720
- Scottish Heart Health Study, 316-317, 318-
 319, 790-793
- Selenium, 444
- Sensitive subpopulations. *See also* Special
 considerations
 identification of, 97-98
- Septicemia, 609, 705
- Serine (dispensable), 591, 593, 594, 597,
 604, 608, 711, 719, 729-730, 736,
 1018-1019
- Serotonin, 608, 706, 731, 732, 916
- Seven Countries Study, 562, 817, 826, 827
- Seventh Day Adventists, 363, 835
- Skeletal health, physical activity and, 66
- Skin cancer, 837
- Sleeping metabolic rate (SMR), 112, 118,
 140, 147, 165, 195
- Snack foods, 118, 732-733
- Socioeconomic status, and reporting of
 dietary intakes, 117
- Sodium, 725
- Soft drinks, 312-313, 789
- Soldiers, 148, 223

- Somnolence, 698, 700, 722, 733
- Sorbitol, 266
- Special considerations. *See also individual nutrients and life-stage groups*
- athletes, 221-223, 660-661
 - chronic diseases, 494
 - disabled individuals, 30, 660
 - dose-response assessment, 100, 101
 - drug interactions, 494
 - identification of, 92, 102
 - infant formula, 45, 283, 457, 461, 463, 469, 621
 - irritable bowel syndrome, 395
 - linoleic acid: α -linoleic acid ratio, 472
 - low carbohydrate diets, 293
 - muscle wasting diseases, 660
 - negative energy balance, 213-215
 - overweight and obesity, 202-213, 216-219
 - phenylketonuria, 728
 - physical activity, 660-661
 - twin pregnancy, 656
 - undernutrition, 220, 221
 - vegetarians, 661-662
 - weight maintenance, 202-204, 216-219
 - weight reduction, 209, 212, 213-215, 219
 - weight restoration, 220-221
- Special Turku Coronary Risk Factor Intervention Project, 811
- Specific Dynamic Action. *See* Thermic effect of food
- Stachyose, 265, 342
- Starch. *See also* Resistant starch
- and cancer risk, 321
 - definition, 267-268
 - and dental caries, 296
 - digestion and digestibility, 269, 272
 - energy yields, 109
 - food sources, 265-266, 294
 - glycemic index, 323
 - insulin sensitivity, 303
 - lipogenesis, 59, 298-301, 302
 - slow release vs. fast release, 382
- Starvation, 276, 277-279, 284, 430, 437, 595, 605, 609, 693, 704
- Stearic acid, 58, 425, 431, 432, 483-484
- Sterol-coenzyme A desaturase, 837
- Sterol regulatory element-binding protein, 545, 562
- Stroke, 59, 230-231, 492-493, 827-828
- Stunting, 221, 701
- Sucrase, 272, 592
- Sucrose, 109, 266, 272, 274, 283, 294, 295, 297, 298-301, 302, 303, 311, 319, 345
- Sugar, 323
- added, 16, 65, 118, 266-267, 294, 295, 303, 312, 314-315, 318-319, 323, 770, 788-789, 790-793, 810, 812-813, 816, 957, 988-991, 1203-1225
 - adverse effects of, 295, 319-321
 - alcohols, 266, 341, 342
 - behavioral effects, 295-296, 323
 - and BMI, 65, 310, 313, 316-319
 - and cancer risk, 55, 319-320, 321, 323
 - and CHD risk, 303, 800-801
 - definition, 266-267
 - and dental caries, 61-62, 296-297, 323
 - and diabetes type 2, 303
 - dietary intakes, 118, 266, 294-295, 323, 988-991, 1206-1209, 1216-1219
 - digestion, 272
 - energy intake from, 65, 118, 273, 307, 310, 313, 314-315, 770
 - epidemiological studies, 800-801
 - extrinsic, 266, 297, 812
 - food sources, 266-267, 294, 312-313
 - glycemic index, 323
 - in high fat, low carbohydrate diets, 810
 - and insulin sensitivity, 303
 - intake assessment, 323
 - intestinal absorption, 273
 - intrinsic, 265
 - lipogenicity, 59, 297-302, 323
 - in low fat, high carbohydrate diets, 788-789, 790-793
 - maximal intake levels, 16, 810, 816
 - and micronutrient intake levels, 788-789, 790-793, 809, 812, 1203-1225
 - and obesity, 307, 310-313, 314-319, 323
 - substitutes, 346, 695, 702-703, 727
 - total, 313, 314-315, 316-317, 789, 792, 809, 813-814
 - uses, 266
- Sugar beet fiber, 383, 394, 838
- Supplements, dietary. *See also individual nutrients*
- bioavailability considerations, 29, 93, 94
 - chronic consumption, 719, 727
 - clinical trials, 27-28, 85
 - data sources on intakes, 941
 - fiber, 345
 - impurities in, 733

intake assessment, 88-89, 104
 physical exercise and, 925-926
 ULs and, 27, 85, 91-92, 104

T

- Tarahumara Indians, 546, 561
 Taste and smell acuity, 722
 Taurine, 608
 Teratogens, 708, 728
 Testosterone, 543
 Thermic effect of food (TEF). *See also individual nutrients*
 age/aging and, 134, 143, 165, 171, 179
 alcohol, 109-110
 defined, 109-110, 114
 and energy expenditure, 114, 115, 116, 150, 165, 171
 and energy requirements, 165, 171, 190, 196-197
 fat, 114
 infants, 165
 lactation and, 196-197
 obesity and overweight and, 133-134, 143
 pregnancy and, 190
 protein, 110, 114
 Thermoregulation, 114, 116, 165-166
 Thiamin, 790-791, 1228-1243
 Threonine (indispensable), 589, 591, 593, 597, 601, 604, 615, 618, 661, 663-665, 666, 668, 671-682, 683, 686, 687, 689, 692, 723, 730-731, 736, 1020-1021
 Threonine dehydrogenase, 678
 Thrombosis, 427
 Thromboxanes, 434, 454, 826
 Thyroid hormones, 608
 Thyroid stimulating hormone, 715
 Toddlers, ages 1 through 3 years. *See Children*
 Tolerable Upper Intake Levels (ULs). *See also UL modeling*
 applicable population, 84, 89
 criteria and proposed values, 12-13
 defined, 3, 22, 23, 27-28, 84, 99
 derivation of, 27, 85-86, 90, 96, 98, 101, 102
 extrapolation on body-weight basis, 34, 47, 85, 86, 101
 fortification of foods and, 27, 85
 not established for macronutrients, 101-104, 107, 224, 694, 770, 940, 946
 offsetting benefits reduction, 103
 supplement use and, 27, 85, 88-89, 91-92
 uses, 27, 84, 85, 936, 940, 945, 947-948
 Total energy expenditure (TEE). *See also Energy expenditure*
 approach used to determine, 151-164, 202-203
 body composition and size and, 132
 coefficients and standard errors, 1200-1202
 components of, 112-116
 data analysis and assumptions for equations, 154-157
 defined, 116
 DLW data, 116, 117, 119-121, 122-123, 138-139, 141, 151-157, 166, 174, 193, 198-199, 201, 291, 1104-1202
 EEPA, 115-116, 117, 133, 138-140, 143-144, 145-146, 147-148
 EER derivation, 149-150, 166, 168-169, 174, 176, 181, 183, 186, 193-195, 201, 202-203, 208
 equations for normal-weight children, 161-164, 1200
 factorial approach, 116, 118-119
 gender differences, 166, 174, 202-203, 204, 206-213, 217, 218-219
 menstrual cycle and, 141
 for obese and overweight individuals, 133, 153, 156-157, 202-204, 209-213, 1168-1182, 1184-1199, 1201-1202
 PAL categories, 116, 157-161, 162-163, 164, 1122-1199
 regression on variables, 159-161, 164, 214
 reported energy intake and, 117-118
 RMR and, 132, 148
 TEF and, 116
 underfeeding studies, 213-215
 uses, 951
 whole-body calorimetry measurements, 120, 122-123, 140
 Toxicity
 age and sensitivity to, 92
 mechanisms of action, 97
 Trans fatty acids
 absorption, 436
 adverse effects of, 436, 455-456, 494-505
 and blood pressure, 504, 506-509
 and cancer, 512-515
 and cardiovascular disease, 503

- and cerebrovascular disease, 503
 - and CHD risk, 58, 423, 504, 510-513
 - controlled feeding trials, 496-499
 - dietary intakes, 436, 479, 835, 960
 - energy contribution, 479, 480
 - epidemiological studies, 510-515
 - evidence considered for estimating requirements, 447, 473
 - excretion, 437
 - and fetal and infant growth, 436, 455
 - food sources, 48, 427-428, 436, 455, 479, 480, 495, 836
 - free-living trials, 500-503
 - function, 427-428
 - hazard identification, 494-504
 - and hemostatic factors, 504, 506-509
 - high-intake diets, 836
 - and LDL oxidation, 504, 506-509
 - and lipid profile, 58, 423, 494-503, 504
 - low-intake diets, 835
 - and Lp(a), 496-503, 510-511
 - measuring intakes, 436
 - metabolism, 436-437
 - and polyunsaturated fatty acid metabolism, 455-456
 - properties, 424, 427
 - reducing intakes, 836
 - research recommendations, 514
 - transport, 436
 - Transamination, 604, 704, 712
 - Transferrin, 609, 610
 - Trauma, 596, 605
 - Trehalose, 266
 - Triacylglycerol or triacylglyceride. *See also*
 - Fat, total; Lipids and lipid metabolism
 - amino acid intake and, 724
 - carbohydrate intakes and, 59, 275, 783
 - and CHD risk, 57-58, 59, 437
 - fat intake and, 777-781
 - fiber intake and, 60, 351, 354, 356, 357, 359, 360, 361, 367-368, 369
 - food sources, 473
 - gluconeogenesis, 275, 278
 - glycemic index and, 302, 322
 - glycerol content, 278, 279
 - hydrolysis of, 429
 - lipoprotein metabolism and, 61, 278
 - low fat, high carbohydrate diets and, 777-781
 - lypolysis, 431
 - monounsaturated fatty acid intake and, 817-818
 - physical exercise and, 60
 - polyunsaturated fatty acids and, 59, 820, 821, 822-823, 826, 828, 830-831
 - protein intake and, 60, 843
 - sugar intake and, 297-301
 - synthesis, 431, 432, 439
 - very low density lipoprotein, 430, 431, 439
 - Tricarboxylic acid (TCA) cycle, 274
 - Triceps skinfold measurements, 125, 128, 1080-1081, 1086-1087, 1092-1093, 1100-1101
 - Trisaccharides, 272
 - Trypsin, 599
 - Tryptophan (indispensable), 589, 591, 593, 608, 616, 663-665, 666, 668, 672-675, 677, 678, 679-682, 686, 687, 689, 692, 704, 705, 706, 707, 709, 710, 726, 731-734, 736, 1022-1023
 - 24-Hour amino acid balance method, 616-617, 670-671, 676, 677
 - 2000 Dietary Guidelines for Americans*, 124, 267
 - Typhoid vaccine, 488-489, 491
 - Tyrosine (conditionally indispensable), 589, 591, 593, 594, 597, 608, 617, 619, 663-665, 666, 668, 671-682, 686, 687, 689, 703, 704, 707, 709, 710, 726, 727, 734-736, 1024-1025
 - Tyrosinemia II, 735
- ## U
- Ubiquitin-protease system, 602
 - UCP1 gene, 145
 - UK National Diet and Nutrition Survey of Children, 314-315, 790-791
 - UL modeling. *See also* Dose-response assessment; Risk assessment models
 - critical endpoint, 93, 98, 99, 101, 102
 - data selection, 98
 - hazard identification, 94-98
 - mathematical models, 85-86
 - nutrient intake assessment, 104
 - risk characterization, 86, 89, 90, 104-105
 - uncertainty assessment, 89, 98, 100-101
 - Ulcerative colitis, 348, 371
 - Uncertainties
 - in AIs, 26, 44
 - amino acid scoring patterns, 688
 - approaches for dealing with, 1244-1249

assessment, 89, 98, 100-101
 case-by-case judgments, 1246-1247, 1248-1249
 in data, 86, 99, 1246
 default options, 1246, 1248-1249
 dose-response assessment, 98, 100-101
 in exposure routes, 98
 extrapolation from one age group to another, 101
 range of estimates applied to, 1246, 1248-1249
 in risk assessment, 86, 87, 91-92, 100-101, 102-103, 1244-1249

Uncertainty factors
 defined, 90, 977
 for energy intake, 224
 inferences from experimental animal studies, 100, 1245-1246
 LOAEL instead of NOAEL, 100-101
 selection of, 87, 99, 100
 sensitivity of individuals, 100
 sources of uncertainty in, 100-101
 subchronic NOAEL to predict chronic NOAEL, 101
 use, 90, 91

Undernutrition, 130, 220
 Underweight, 121, 130, 190, 811
 United Kingdom Department of Health, 266
 United Nations University, 621, 634
 United States
 fiber definitions, 340
 human milk intake and composition, 172-173
 physical activity recommendations, 882-883

Urea, 114, 594, 601, 603, 604-605, 611, 620, 650, 657, 671, 684, 693-694, 699, 712

Uric acid, 603, 604

Urinary C-peptide, 322, 353, 361

U.S. Department of Agriculture, 49, 124, 266, 294, 344, 346, 391, 479, 771, 882

U.S. Department of Health and Human Services
 dietary intake survey data, 49
 Office of Disease Prevention and Health Promotion, 1
 2000 *Dietary Guidelines*, 124, 882-883

U.S. Department of Health, Education, and Welfare, 882

U.S. Environmental Protection Agency, 1246

V

Vaccenic acid, 426, 428

Valine (indispensable), 589, 591, 593, 597, 663-665, 666, 668, 672-675, 677, 678, 679-682, 686, 687, 689, 704-711, 726, 736, 1026-1027

Vegetables. *See* Fruits and vegetables

Vegetarians, 372, 466, 661-662, 835, 975, 1077

Very low density lipoprotein (VLDL), 61, 430, 439, 545
 remnant, 431, 544

Vision, 439, 440, 468, 711, 714, 720, 722, 729

Vitamin A, 424, 609, 785, 788, 789, 790-793, 811, 812, 813, 1204-1211, 1214-1221, 1224-1225

Vitamin B₆, 771, 785, 788, 789, 790-793, 1228-1243

Vitamin B₁₂, 771, 785, 789, 790-791, 813, 835, 1228-1243

Vitamin C, 771, 788, 789, 790-791, 808, 813, 816, 1228-1243

Vitamin D, 424, 790-791, 811, 812, 840, 841

Vitamin E, 424, 444, 493, 785, 789, 790-793, 811, 812, 813, 829, 1204-1211, 1214-1221, 1224-1225

Vitamin K, 424, 788

VLDL cholesterol, 843

W

Waist circumference, 124-125, 127, 1080-1081, 1084-1085, 1094-1099, 1102-1103

Water
 and laxation, 370, 398
 physical exercise and, 925-926

Weight. *See also* Obesity and overweight; Reference weights and heights; Underweight; *individual life-stage groups*
 adaptation, 150
 adjustment of DRIs based on, 34
 adults, 143, 183, 184, 220, 1078-1081, 1088-1091
 age/aging and, 143, 167
 amino acids and, 697, 698, 700, 707, 709, 713, 721, 724, 730, 731-732, 734

- BEE and, 116, 141, 150, 183, 184, 186, 206-213, 888
- BMI and, 1080-1081
- body fat and, 1090-1091
- and chronic disease, 224, 226-229
- and diabetes type 2, 802
- energy balance and, 65, 150, 212, 214, 220
- and energy expenditure, 116, 132, 135, 141, 150, 157, 159-161, 183, 184, 186, 206-213, 215, 216-219, 889, 891-895, 951
- energy intake and, 121, 223-224, 793-794, 951-952
- and energy requirements, 112, 183, 184, 220
- epidemiological studies, 382-383
- fat intake and, 441, 452, 773-776, 809
- fiber intake and, 65, 339, 351-352, 370, 382-384
- gain, 47-48, 110, 121, 143, 144, 167, 186, 223-224, 226-229, 452, 650, 652, 653, 654, 655, 697, 698, 709, 730-732, 734, 802, 951-952
- gender differences, 1078-1081, 1088-1091
- genetic factors, 144, 452
- hypocaloric vs. isocaloric diets, 772
- intervention studies, 311, 383-384
- loss, 61, 65, 121, 199-200, 204, 209, 212, 215, 217, 219, 225, 311, 313, 351-352, 370, 383, 721, 843, 951
- low fat, high carbohydrate diets, 311, 773-777
- maintenance, 149, 202-209, 216-219, 382-383, 441, 773-777, 951-952
- measurement confounding, 202-204
- metabolic rate and, 112, 113, 135, 138
- overeating and, 121, 151
- physical exercise and, 61, 115-116, 213-215, 452, 773
- pregnancy, 47-48, 188, 190, 191, 192, 196, 650, 652, 653, 655, 709
- protein (nitrogen) and, 598, 612, 843
- rapid loss, 217
- recommended, 117
- regain after loss, 135
- restoration, 220-221
- stabilization, 138
- and TEE, 159-161
- velocity, 142
- Whites. *See* Caucasians
- Whole-body calorimetry, 120, 122-123
- Women. *See also* Gender differences; Lactation; Pregnancy
- bone mineral density, 841, 928
- calcium, 789, 841
- carbohydrate intakes compared to other nutrients, 1238-1243
- CHD, 363, 364
- colon cancer, 373
- diabetes type 2, 380, 381
- energy expenditure, 140
- fiber, 363, 364, 373, 380, 381
- glycemic load, 303
- menopause, 141, 143, 921
- metabolic rate, 140, 141
- nutrient intakes with added sugars, 1218-1225
- oral contraceptives, 921
- physical activity, 138, 140, 894, 913, 921, 928
- premenopausal, 140, 141
- protein intakes, 695, 841
- reference weights and heights, 126
- weight control, 352, 773
- Women's Health Initiative Observational Study, 913
- World Cancer Research Fund, 321
- World Health Organization, 84, 110, 121, 621, 634, 648, 684, 913

X

Xylose, 345

Y

Youth Risk Behavior Study, 923

Z

Zinc, 221, 391, 394, 397-398, 705, 721-723, 771, 785, 789, 790-793, 812, 813-814, 840, 1204-1209, 1212-1219, 1222-1225, 1228-1243

Zutphen Elderly Study, 381, 483, 826, 827